Envoy Medical, Inc PRE 14A, filed Mar 23, 2026
Envoy Medical, Inc. (COCH)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
SCHEDULE
________________________________
Proxy Statement Pursuant to Section 14(a) (Rule 14a-101) of the
Securities Exchange Act of 1934
|
Filed by the Registrant |
☒ |
|
|
Filed by a Party other than the Registrant |
☐ |
Check the appropriate box:
|
☒ |
Preliminary Proxy Statement |
|
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6I(2)) |
|
|
☐ |
Definitive Proxy Statement |
|
|
☐ |
Definitive Additional Materials |
|
|
☐ |
Soliciting Material Pursuant to §240.14a-12 |
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
☒ |
No fee required. |
|
|
☐ |
Fee paid previously with preliminary materials. |
|
|
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
PRELIMINARY MATERIALS
Subject to Completion
Envoy Medical, INC.
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY [12], 2026
TO THE STOCKHOLDERS OF Envoy Medical, INC.:
Please Take Notice that Envoy Medical, Inc. (“Envoy Medical” or the “Company”) will hold its 2026 Annual Meeting of Stockholders at the offices of Fredrikson & Byron, PA, 60 South Sixth Street, Suite 1500, Minneapolis, MN 55402 on May [12], 2026 at 3:00 p.m. local time. Envoy Medical is holding this meeting for the purpose of considering and taking appropriate action with respect to the following:
1. To elect two Class III director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve a term that continues until the 2029 annual meeting of stockholders;
2. To ratify the appointment of Grant Thornton LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2026;
3. To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation;
4. To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan;
5. To approve an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan;
6. To approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stock underlying such warrants, that were issued in a transaction that was completed on February 12, 2026; and
7. To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the meeting.
Holders of record of Class A Common Stock at the close of business on March 13, 2026 will be entitled to vote at the meeting or any adjournments thereof. Your attention is directed to the Proxy Statement accompanying this Notice for a more complete statement of the matters to be considered at the meeting. A copy of our Annual Report on Form 10-K for the year ended December 31, 2025 also accompanies this Notice.
|
By Order of the Board of Directors, |
||
|
/s/ Chuck R. Brynelsen |
||
|
Date: [April 2], 2026 |
Chairman of the Board of Directors |
Your vote is important. To vote your shares, please vote by telephone or Internet, as directed in the Proxy Statement, or if you received a proxy card or voting instruction form by mail, please complete, sign, date and mail the proxy card or voting instruction form promptly in the envelope provided. The prompt return of proxies will save Envoy Medical the expense of further requests for proxies.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY [12], 2026:
This Notice, the Proxy Statement, and the Annual Report on Form 10-K are available at www.iproxydirect.com/coch and on the Investor Relations section of Envoy Medical’s website at ir.envoymedical.com.
Envoy Medical, INC.
4875 White Bear Parkway
White Bear Lake, MN 55110
PROXY STATEMENT
2026 Annual Meeting OF STOCKHOLDERS
TO BE HELD ON MAY [12], 2026
This Proxy Statement is furnished in connection with the solicitation of proxies by Envoy Medical, Inc., a Delaware corporation (“Envoy Medical,” the “Company,” “we,” “our” or “us”), for use at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at the offices of Fredrikson & Byron, PA, 60 South Sixth Street, Suite 1500, at 3:00 p.m. Central Time on May [12], 2026.
Purposes of the Annual Meeting
The purposes of the Annual Meeting are:
1. To elect two Class III director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve a term that continues until the 2029 annual meeting of stockholders;
2. To ratify the appointment of Grant Thornton LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2026;
3. To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation;
4. To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan;
5. To approve an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan;
6. To approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stock underlying such warrants, that were issued in a transaction that was completed on February 12, 2026; and
7. To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the meeting.
Action may be taken on any one of the foregoing proposals on the date specified above for the Annual Meeting, or on any date or dates to which the Annual Meeting may be adjourned.
Notice and Access Delivery
In accordance with rules and regulations adopted by the U.S. Securities and Exchange Commission (the “SEC”), we have elected to provide our beneficial owners and stockholders of record access to our proxy materials over the Internet. Beneficial owners are stockholders whose shares are held in the name of a broker, bank, or other nominee (i.e., in “street name”). Accordingly, a Notice of Internet Availability of Proxy Materials (the “Notice”) will be mailed on or about [April 2], 2026 to our beneficial owners and stockholders of record who owned our Class A Common Stock at the close of business on March 13, 2026. Beneficial owners and stockholders of record will have the ability to access the proxy materials on a website referred to in the Notice or to request a printed set of the proxy materials be sent to them by following the instructions in the Notice. Beneficial owners and stockholders of record who have previously requested to receive paper copies of our proxy materials will receive paper copies of the proxy materials instead of a Notice.
You can choose to receive our future proxy materials electronically by visiting www.iproxydirect.com. Your choice to receive proxy materials electronically will remain in effect until you instruct us otherwise by following the instructions contained in your Notice and visiting www.iproxydirect.com or calling 866-752-VOTE (8683).
Solicitation
This solicitation is made by Envoy Medical, and Envoy Medical will pay the cost of soliciting proxies for the Annual Meeting. In addition to soliciting proxies by mail, we may solicit proxies personally or by telephone, email, facsimile or other means of communication by our directors, officers and employees. These persons will not specifically be compensated for these activities, but they may be reimbursed for reasonable out-of-pocket expenses in connection
1
with this solicitation. We will not specifically engage any employees or paid solicitors for the purpose of soliciting proxies for the Annual Meeting. We will arrange with brokerage firms and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial owners of shares held of record by these persons. We will reimburse these brokerage firms, custodians, nominees and fiduciaries for reasonable out-of-pocket expenses incurred by them in connection with this solicitation.
Record Date and Shares Outstanding
Only holders of record of our Class A Common Stock at the close of business on March 13, 2026 (the “Record Date”) will be entitled to vote at the Annual Meeting or any adjournments thereof. As of the Record Date, there were 76,881,110 shares of our Class A Common Stock outstanding and entitled to vote. Each share of Class A Common Stock entitles the holder thereof to one vote upon each matter to be presented at the Annual Meeting.
If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy using the enclosed proxy card (if you received paper copies of the proxy materials), vote by proxy over the telephone, or vote by proxy over the Internet. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by proxy.
• To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive.
• If you received paper copies of the proxy materials, to vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.
• To vote over the telephone, dial toll-free 866-752-VOTE (8683) and follow the recorded instructions. Please have available the 16-Digit Control Number from the enclosed proxy card, if you received one, or from your Notice. Your vote must be received by 11:59 p.m., Eastern Time (10:59 p.m., Central Time) on [May 11], 2026, to be counted.
• To vote over the Internet, go to www.iproxydirect.com to complete an electronic proxy card. Please have available the 16-Digit Control Number from the enclosed proxy card, if you received one, or from your Notice. Your vote must be received by 11:59 p.m., Eastern Time (10:59 p.m., Central Time) on [May 11], 2026, to be counted.
We are providing Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.
If you are a beneficial owner of shares registered in the name of your broker, bank, or other nominee, you may have received a proxy card and voting instructions with these proxy materials from that organization rather than from us. Simply complete and mail the proxy card to ensure that your vote is submitted to your broker. Alternatively, you may vote by telephone or over the Internet as instructed by your broker. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker. Follow the instructions from your broker included with these proxy materials or contact your broker to request a proxy form.
Quorum
A quorum, consisting of a majority of the outstanding shares of our Class A Common Stock entitled to vote at the Annual Meeting, must be present in person or by proxy before any action can be taken by the stockholders at the Annual Meeting. Abstentions and withheld votes are counted as present and entitled to vote for purposes of determining a quorum.
If you are a beneficial owner of shares registered in the name of your broker, bank, or other nominee, such shares may be voted by the broker on “routine” matters, which includes ratification of the appointment of our independent registered public accounting firm (Proposal 2). All other proposals in this Proxy Statement are considered “non-routine.” Your broker will not be able to vote your shares on non-routine matters being considered at the Annual Meeting unless you
2
have given instructions to your broker prior to the Annual Meeting on how to vote your shares. When the broker does not obtain direction to vote the shares, the broker’s abstention is referred to as a “broker non-vote.” Broker non-votes will be considered present for quorum purposes at the Annual Meeting.
So long as a quorum is present at the beginning of the Annual Meeting, the stockholders present may continue to transact business until adjournment, even if enough stockholders have left the Annual Meeting to leave less than a quorum, and even if any stockholder present in person or by proxy refuses to vote or participate in the Annual Meeting. If the Annual Meeting is adjourned for any reason, the approval of the proposals may be considered and voted upon by stockholders at the subsequent reconvened meeting. All proxies will be voted in the same manner as they would have been voted at the original Annual Meeting except for any proxies that have been properly withdrawn or revoked.
Board of Directors Recommendation and Voting of Proxies
The Board of Directors of the Company (the “Board”) recommends a vote:
• “FOR” the election of each of the two Class III director nominees (Proposal 1).
• “FOR” ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2026 (Proposal 2).
• “FOR” approval, on an advisory basis, of named executive officer compensation (Proposal 3).
• “FOR” approval of the proposed amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan (Proposal 4).
• “FOR” approval of the proposed amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan (Proposal 5).
• “FOR” approval, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stock underlying such warrants, that were issued in a transaction that was completed on February 12, 2026 (Proposal 6 or the Issuance Proposal).
If you complete and submit your proxy before the Annual Meeting, the persons named as proxy agents will vote the shares represented by your proxy in accordance with your instructions. If you submit a proxy without giving voting instructions, your shares will be voted in the manner recommended by the Board on all matters presented in this Proxy Statement. If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named as proxy agents will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.
Vote Required
For the election of directors (Proposal 1), you have the option to vote “For” or “Withhold” authority to vote for any of the director nominees. Assuming a quorum is present, a plurality of the votes cast is required for the election of directors. This means that the two Class III director nominees with the most votes will be elected. If you “Withhold” authority to vote on any or all nominees, your vote will have no effect on the outcome of the election. If you hold your shares in “street name” and do not provide instructions to your broker, your broker will not have discretionary authority with respect to the proposal to elect directors and will therefore provide a “broker non-vote.” Since broker non-votes are not deemed votes cast, they will have no effect on the outcome of the election.
For the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm (Proposal 2), you have the option to vote “For,” “Against” or “Abstain” from voting. Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of Envoy Medical represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm. If you “Abstain” from voting with respect to this proposal, your
3
shares will be counted as present and entitled to vote and your vote will have the same effect as a vote against the proposal. If you hold your shares in “street name” and do not provide instructions to your broker, your broker will have discretionary authority to vote your shares with respect to this proposal.
For the approval, on an advisory basis, of the compensation of our named executive officers (Proposal 3), you have the option to vote “For,” “Against” or “Abstain” from voting. Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve the compensation of our named executive officers. If you mark “Abstain” from voting with respect to this proposal, your shares will be counted as present and entitled to vote and your vote will have the same effect as a vote against the proposal. If you hold your shares in “street name” and do not provide instructions to your broker, your broker will not have discretionary authority to vote your shares with respect to this proposal and will therefore provide a “broker non-vote.” Since broker non-votes are not deemed present and entitled to vote on this proposal, they will have no effect on the outcome of the proposal. The vote on approval of the compensation of our named executive officers is an advisory vote, which means that the result of the vote is not binding on the Company, the Board, or the Compensation Committee. To the extent there is any significant vote against our named executive officer compensation as disclosed in this Proxy Statement, the Board and the Compensation Committee will evaluate whether any actions are necessary to address the concerns of stockholders.
For the approval of the proposed amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan (Proposal 4) and the proposed amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan (Proposal 5), you have the option to vote “For,” “Against” or “Abstain” from voting each proposal. Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve Proposal 4 and Proposal 5. If you mark “Abstain” from voting with respect to this proposal, your shares will be counted as present and entitled to vote and your vote will have the same effect as a vote against the proposal. If you hold your shares in “street name” and do not provide instructions to your broker, your broker will not have discretionary authority to vote your shares with respect to this proposal and will therefore provide a “broker non-vote.” Since broker non-votes are not deemed present and entitled to vote on these proposals, they will have no effect on the outcome of the proposal. The vote on approval of these proposals is a binding vote, which means that the proposals will be adopted if approved by the stockholders or not adopted if not approved by the stockholders.
For the Issuance Proposal (Proposal 6), you have the option to vote “For,” “Against” or “Abstain” from voting for such proposal. Assuming a quorum is present, the affirmative vote of a majority of all outstanding shares of Class A Common Stock, either in person or by proxy, and entitled to vote is required to approve Issuance Proposal. If you mark “Abstain” from voting with respect to this proposal, your shares will be counted as present and entitled to vote and your vote will have the same effect as a vote against the proposal. If you hold your shares in “street name” and do not provide instructions to your broker, your broker will not have discretionary authority to vote your shares with respect to this proposal and will therefore provide a “broker non-vote.” Since broker non-votes are not deemed present and entitled to vote on these proposals, they will have no effect on the outcome of the proposal. The vote on approval of these proposals is a binding vote, which means that the proposals will be adopted if approved by the stockholders or not adopted if not approved by the stockholders.
Revocability of Proxies
Any person giving a proxy for the Annual Meeting has the power to revoke it at any time before it is voted. If you are a record holder of your shares, you may revoke your proxy in any one of the following ways: (1) sending a written notice of revocation dated after the date of the proxy to our Corporate Secretary, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110; (2) submitting a properly signed proxy with a later date; (3) submitting a new vote by telephone or Internet; or (4) attending the Annual Meeting and voting in person. Attendance at the Annual Meeting will not constitute a revocation of a proxy unless you request a ballot and vote at the Annual Meeting.
If you are a beneficial owner of shares registered in the name of your broker, bank, or other nominee, you must contact them in order to find out how to revoke your proxy.
4
Householding
The SEC has adopted rules that permit companies and brokers, banks and other nominees to satisfy the delivery requirements for proxy statements and annual reports, with respect to two or more stockholders sharing the same address and who do not participate in electronic delivery of proxy materials, by delivering a single copy of such documents addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
Brokers, banks and other nominees may be “householding” Company proxy materials. This means that only one copy of the proxy materials may have been sent to multiple stockholders in a household. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report from the other stockholder(s) sharing your address, please: (i) notify your broker, bank or other nominee, (ii) direct your written request to our Chief Financial Officer, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110, or (iii) contact us at (877) 900-3277. The Company will undertake to deliver promptly, upon any such oral or written request, a separate copy of the proxy materials to a stockholder at a shared address to which a single copy of these documents was delivered. Stockholders who currently receive multiple copies of proxy materials at their address and would like to request householding of their communications should notify their broker, bank or other nominee, or contact us at the above address or phone number.
Other Business
The Board currently has no knowledge of any matters to be presented at the Annual Meeting other than those referred to in this Proxy Statement. The solicited proxies give discretionary authority to the proxy agents named therein to vote in accordance with the recommendation of the Board if any other matters are presented.
5
FINANCIAL INFORMATION
Our Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC, including, but not limited to, the balance sheets and the related statements of operations, changes in stockholders’ equity and cash flows for Envoy Medical as of and for the years ended December 31, 2025 and 2024 accompanies these materials. A copy of the 2025 Annual Report on Form 10-K may be obtained without charge upon request to our Chief Financial Officer, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110. Our 2025 Annual Report on Form 10-K is also available on our website at ir.envoymedical.com.
6
PROPOSAL NO. 1
ELECTION OF DIRECTORS
Our business and affairs are managed under the direction of the Board, which consists of six members. Mr. Brynelsen serves as Chairman of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to the Company’s management. The Board meets on a regular quarterly basis and on an ad hoc basis as required.
In accordance with the terms of our Certificate of Incorporation and Bylaws, the Board is divided into three classes with staggered three-year terms, as follows:
• The Class I directors are Michael Crowe and Mona Patel, and their term expires at the annual meeting of stockholders to be held in 2027;
• The Class II directors are Janis Smith-Gomez and Chuck R. Brynelsen, and their term will expire at the annual meeting of stockholders to be held in 2028; and
• The Class III directors are Brent T. Lucas and Susan J. Kantor, and their term will expire at the annual meeting of stockholders to be held in 2026, subject to reelection at the Annual Meeting to serve until 2029.
Mr. Lucas and Ms. Kantor will be standing for reelection at the Annual Meeting. Each of them was previously elected at the Special Meeting of Stockholders held in September 2023.
At each annual meeting of stockholders, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute the Board will be determined exclusively by the Board. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of one-third of the directors. No decrease in the number of directors constituting the Board will shorten the term of any incumbent director. Our directors may be removed, at any time, but only for cause and only by the affirmative vote of at least a majority of the total voting power of the outstanding shares of voting stock of the Company then entitled to vote at an election of directors.
Subject to applicable law and the terms of the Certificate of Incorporation and Bylaws, any vacancy on the Board shall be filled only by the Board and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified.
The current composition of the Board is as follows:
|
Name of Nominee |
Age |
Class |
Position Held with Envoy Medical, Inc. |
Director Since |
||||
|
Michael Crowe |
62 |
Class I |
Director |
2024 |
||||
|
Mona Patel |
58 |
Class I |
Director |
2023 |
||||
|
Janis Smith-Gomez |
58 |
Class II |
Director |
2023 |
||||
|
Chuck R. Brynelsen |
69 |
Class II |
Director; Chairman of the Board |
2023 |
||||
|
Brent T. Lucas |
44 |
Class III |
Director; Chief Executive Officer |
2023 |
||||
|
Susan J. Kantor |
70 |
Class III |
Director |
2021 |
The Board has determined that each of Michael Crowe, Mona Patel, Janis Smith-Gomez, Chuck R. Brynelsen, and Susan J. Kantor qualifies as an independent director under the rules of the Nasdaq Stock Market (the “Nasdaq Listing Rules”). Accordingly, the Board is and will be composed of a majority of independent directors.
Set forth below is background information for each director (including the current Class III nominees):
Class III Director Nominees
Brent T. Lucas. Brent T. Lucas has served as our Chief Executive Officer and a member of the Board since the closing of the Business Combination in September 2023. At the time of the Business Combination Mr. Lucas was the Chief Executive Officer (since 2015) and Board member of Envoy Medical Corporation (since 2016). Mr. Lucas brings 19 years of experience in active implantables in the hearing health industry, having served in various roles with Envoy Medical Corporation and gained a tremendous amount of specialized experience
7
and industry-specific knowledge, working his way up from an intern to CEO. Mr. Lucas is currently one of the longest-tenured CEOs in the hearing industry. Mr. Lucas received his bachelor’s degree from the University of St. Thomas and Juris Doctor degree from the Mitchell Hamline School of Law.
The Board believes Mr. Lucas is qualified to serve as a member of the Board given his specialized experience and knowledge in the hearing and medical device industries as Legacy Envoy Medical’s Chief Executive Officer.
Susan J. Kantor. Susan J. Kantor has served as a member of the Board since March 2021. Ms. Kantor has experience leading international finance, tax, treasury, risk, compliance and technology enablement for global services organizations. She was an Advisory Partner for PwC from 2011 to 2016, a Partner and CFO & Treasurer of PRTM Management Consultants from 1997 to 2011, and was previously a CFO/senior financial executive at corporate strategy and operations consulting firms Monitor Group and BCG, as well as Parexel International, a clinical research organization. She began her career in the audit practices at EY and PWC, where she provided audit services for over 12 years to privately held and publicly held companies across the industrial, life sciences and retail and consumer sectors. During her time at PRTM, she completed several successful M&A transactions in the U.S. and abroad, including the sale PRTM’s global business to PwC in 2011. Ms. Kantor previously served on the board of Teknor Apex Company, a privately-held material science company and on the board and as Audit Committee Chair of Guest Services Inc., a privately held hospitality company and on the board and Audit Committee of Lionbridge Technologies, Inc., a publicly-traded company. She received her bachelor’s degree from Grove City College in Accounting and Business Administration and her CPA in Massachusetts.
The Board believes Ms. Kantor is qualified to serve on the Board due to her extensive background and expertise in global financial and tax matters. Ms. Kantor qualifies as a “financial expert” and has served as the Chair of the Audit Committee since March 2021.
Class I and Class II Directors
Chuck R. Brynelsen. Chuck R. Brynelsen has served as the Chairman of the Board since the closing of the Business Combination. Mr. Brynelsen has extensive experience in the medical device industry, including most recently serving as Senior Vice President and President of Abbott Vascular from 2017 to 2021. Since 2015 he has also been a Venture Partner of SpringRock Ventures, an investment firm that focuses on digital health, devices, services, oral health, SAAS, consumerization/ecommerce of healthcare, IT, wellness, HIPAA and other innovative companies improving general health. Mr. Brynelsen has also served on private companies’ boards of directors, including Alebra Technologies since 2010 and Neuspera Medical from 2022 to 2023. Mr. Brynelsen previously served as Senior Vice President and President of Medtronic Early Technologies from 2015 to 2016, as the Global President of Covidien Early Technologies from 2013 to 2015, and as the Chief Executive Officer of IntraPace from 2005 to 2012. Earlier in his career, Mr. Brynelsen held various commercial, corporate, international, and general management leadership roles across Medtronic from 1981 to 2005.
The Board believes Mr. Brynelsen is qualified to serve as a member of the Board due to his extensive experience in the management of a multinational public company in the medical device industry, including significant product development, clinical/regulatory, manufacturing, business development and strategic planning experience. He also provides valuable insights into operating in highly regulated global healthcare markets.
Michael Crowe. Michael Crowe has decades of experience in the medical device industry with a focus on operations. Since March 2023, Mr. Crowe has served as Senior Vice President Operations for Bioventus LLC. Previously, he served as Vice President Operations for Abbott Vascular from January 2015 to March 2023. Mr. Crowe earlier served in similar roles for Caris Life Sciences, Covidien Devices, Johnson & Johnson, Iomega Corporation, and SKF USA, Inc. Mr. Crowe earned a bachelor’s degree in engineering from the University of Louisville and an MBA from Duke University.
The Board believes Mr. Crowe is qualified to serve as a member of the Board due to his wide-ranging experience in the management and operations of multinational public companies in the medical device industry, including significant experience overseeing distribution, supply chain and sourcing, facilities, engineering, customer service, reimbursement services, and product launch, which the Board believes will be vital to the Company’s next stages of development.
8
Mona Patel. Mona Patel has served as a member of the Board since the closing of the Business Combination. Ms. Patel has over 30 years of experience with medical devices in marketing, market development, clinical education and mergers and acquisitions. Most recently, Ms. Patel was the Vice President of Marketing and Clinical Education at Boston Scientific in their neuromodulation division, where she helped build the start-up into a market leader with approximately $1 billion in sales. While at Boston Scientific, she introduced the first rechargeable spinal cord stimulator into the market, helped convert the market from non-rechargeable to rechargeable stimulators, and launched the first rechargeable deep brain stimulator for Parkinson’s disease. Prior to joining Boston Scientific, Ms. Patel worked in various positions at Guidant in marketing and business development, through which she acquired and licensed a portfolio of technologies that became the Guidant Cardiac and Vascular surgery division, including the acquisition of two med-tech start-ups. As a marketing leader, she drove the adoption of a new procedure, endoscopic vessel harvesting, to become the gold standard for cardiac surgery. She began her career as an engineer for Abbott Labs. Ms. Patel earned a BSE in Mechanical Engineering from the University of Michigan and an M.B.A. from the University of Pennsylvania, Wharton School of Business.
The Board believes Ms. Patel is qualified to serve on the Board due to her extensive background in the medical devices field and expertise in marketing and business development.
Janis Smith-Gomez. Janis Smith-Gomez has served as a member of the Board since the closing of the Business Combination. Ms. Smith-Gomez has more than 30 years of experience in marketing and innovation, positioning global brands for growth and competitive advantage, contributing to her strong business acumen and stakeholder insights focus. From 2006 to 2022, Ms. Smith-Gomez held a variety of leadership positions at Johnson & Johnson across medical devices and consumer health, where she focused on building brands, launch excellence and innovative marketing strategies for revenue and market share growth. In her most recent role at Johnson & Johnson as the Vice President of Global Brand Experience, she led the brand identity efforts to evolve the $27 billion medical devices business into a leading patient-centered, customer-focused, digitally powered med-tech innovator. As the Vice President of U.S. Marketing for Ethicon LLC, a subsidiary of Johnson & Johnson, from 2014 – 2018, Ms. Smith-Gomez returned the business to growth and strengthened customer engagement. Prior to working at Johnson & Johnson, Ms. Smith-Gomez held the roles of Vice President of Marketing at Mars, Incorporated, Senior Director at Kraft Foods, and Director of Marketing at PepsiCo, Inc. Ms. Smith-Gomez started her career in consulting with Booz, Allen & Hamilton and completed a summer internship with Procter & Gamble. Ms. Smith-Gomez is currently also Chair of the Board and an Independent Director of The Honey Pot Company, a subsidiary of Compass Diversified and a member of the board of trustees of several non-profit organizations, including the New York Academy of Medicine, and Black Public Media. She also previously served as a trustee for Kent Place School and Citymeals on Wheels and a board member of the Vanderbilt University Parents and Family Association. Ms. Smith-Gomez received her bachelor’s degree in Professional Option: Business and her M.B.A. from the University of Chicago.
The Board believes Ms. Smith-Gomez is qualified to serve on the board due to her extensive experience in the medical devices industry, her strategic planning expertise and her successful career as a senior executive, commercial leader and marketing strategist driving brand relevance and sustainable financial and operational performance.
Vote Required
Assuming a quorum is present, the affirmative vote of a plurality of the votes cast at the Annual Meeting is required for the election of each Class III director.
THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE
FOR THE CLASS III DIRECTOR NOMINEES NAMED ABOVE.
9
PROPOSAL NO. 2
RATIFICATION OF APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Grant Thornton LLP (“Grant Thornton”), an independent registered public accounting firm, has been appointed by our Audit Committee to serve as the auditor for our consolidated financial statements.
Notwithstanding the appointment of Grant Thornton, and even if our stockholders ratify the appointment, our Audit Committee, in its discretion, annually reviews the engagement of our auditor firm and may appoint another independent registered public accounting firm at any time during our fiscal year if our Audit Committee believes that such a change would be in the best interests of our Company and our stockholders.
At the Annual Meeting, our stockholders are being asked to ratify the appointment of Grant Thornton as our independent registered public accounting firm for our fiscal year ending December 31, 2026. Our Audit Committee is submitting the appointment of Grant Thornton to our stockholders because we value our stockholders’ views on our independent registered public accounting firm and as a matter of good corporate governance.
Envoy Medical has been advised that one or more representatives of Grant Thornton will be present at the Annual Meeting, will have an opportunity to make a statement and will be available to respond to appropriate questions from our stockholders.
If our stockholders do not ratify the appointment of Grant Thornton, the Audit Committee may reconsider the appointment.
Grant Thornton, an independent registered public accounting firm, has audited the Company’s financial statements for the years ended December 31, 2025 and 2024. The engagement agreement entered into with Grant Thornton is subject to mediation and arbitration procedures as the sole method for resolving disputes.
Ratification of the appointment of Grant Thornton as the Company’s independent registered public accounting firm is not required to be submitted to our stockholders for a vote. The Sarbanes-Oxley Act of 2002 requires the Audit Committee to be directly responsible for the appointment, compensation and oversight of the audit work of the independent registered public accounting firm. However, the Board is submitting this matter to the stockholders for ratification as a matter of good corporate governance.
If the appointment of Grant Thornton is not ratified by the stockholders at the Annual Meeting, the Audit Committee may reconsider whether to retain Grant Thornton and may retain Grant Thornton or another firm without resubmitting the matter to the Company’s stockholders. Even if the stockholders vote in favor of ratification of the appointment, the Audit Committee may, in its discretion, direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and the stockholders.
Representatives of Grant Thornton regularly attend meetings of the Audit Committee. The Audit Committee pre-approves and reviews audit and non-audit services performed by Grant Thornton, as well as the fees charged by Grant Thornton for such services. In its pre-approval and review of non-audit service fees, the Audit Committee considers, among other factors, the possible effect of the performance of such services on Grant Thornton’s independence. To avoid potential conflicts of interest, publicly traded companies are prohibited from obtaining certain non-audit services, such as bookkeeping or actuarial services, from its independent registered public accounting firm. In 2024 and 2025, we did not obtain any of these prohibited services from Grant Thornton. For additional information concerning the Audit Committee and its relationship with Grant Thornton, see “Corporate Governance” and “Audit Committee Report” below.
10
Audit and Non-Audit Fees Billed to the Company by Independent Registered Public Accounting Firm
The following table summarizes the fees we were billed for audit and non-audit services rendered by Grant Thornton for 2025 and 2024.
|
For the Years Ended |
||||||
|
December 31, |
December 31, |
|||||
|
Audit Fees(1) |
$ |
555,830 |
$ |
550,028 |
||
|
Audit-Related Fees |
$ |
— |
$ |
— |
||
|
Tax Fees(2) |
$ |
— |
$ |
— |
||
|
All Other Fees |
$ |
— |
$ |
— |
||
|
Total |
$ |
555,830 |
$ |
550,028 |
||
____________
(1) Audit Fees. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and the reviews of our quarterly reports on Form 10-Q and services that are normally provided by our independent registered public accounting firm in connection with statutory and regulatory filings, including in connection with review of registration statements and consents.
Audit Committee Pre-Approval Policies and Procedures
Before an independent registered public accounting firm is engaged by the Company to render audit or non-audit services, the Audit Committee must review the terms of the proposed engagement and pre-approve the engagement. The Audit Committee may delegate authority to one or more of the members of the Audit Committee to provide these pre-approvals for audit or non-audit services, provided that the person or persons to whom authority is delegated must report the pre-approvals to the full Audit Committee at its next scheduled meeting. Audit Committee pre-approval of non-audit services (other than review and attest services) is not required if those services fall within available exceptions established by the SEC.
The Audit Committee pre-approved all audit, audit-related, tax and other services provided by Grant Thornton LLP for 2025 and 2024 and the estimated costs of those services. Actual amounts billed, to the extent in excess of the estimated amounts, were periodically reviewed and approved by the Audit Committee.
Pre-Approval Policy
The charter of the Audit Committee requires the pre-approval of all non-audit services before any such non-audit services are performed for the Company. The charter of the Audit Committee is posted on the Company’s website at ir.envoymedical.com/governance.
Vote Required
Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of Envoy Medical represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to ratify the appointment of Grant Thornton as our independent registered public accounting firm.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
11
PROPOSAL NO. 3
ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION
The Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), require companies to provide their stockholders with the opportunity to vote to approve, on a non-binding, advisory basis, the compensation of their named executive officers.
We seek to align the interests of our named executive officers with the interests of our stockholders. We have designed our compensation program to reward our named executive officers for their individual performance and contributions to our overall business objectives. The vote on this resolution is not intended to address any specific element of compensation. Instead, the vote relates to the overall compensation of our named executive officers, as described in this Proxy Statement in accordance with the compensation disclosure rules of the SEC.
Accordingly, we ask our stockholders to vote on the following resolution at the Annual Meeting:
“RESOLVED, that the Company’s stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the summary compensation table and the other related tables and disclosure.”
While the Board and especially the Compensation Committee intend to carefully consider the results of the voting on this proposal when making future decisions regarding executive compensation, the vote is not binding on the Company or the Board and is advisory in nature. To the extent there is any significant vote against the compensation of our named executive officers, the Board and the Compensation Committee will evaluate what actions may be necessary to address our stockholders’ concerns.
Vote Required
Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of Envoy Medical represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve the compensation of our named executive officers. This vote is advisory and is not binding on the Company, the Board or the Compensation Committee.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE
FOR THE APPROVAL OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS.
12
PROPOSAL NO. 4
AMENDMENT TO ENVOY MEDICAL INC. 2023 EQUITY INCENTIVE PLAN
The Board has approved, subject to stockholder approval, an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan (the “2023 Plan”), to authorize an additional 6,000,000 shares of Class A Common Stock for issuance under the Plan.
Proposed Changes
Under its existing terms, 4,000,000 shares of Class A Common Stock are reserved for issuance under the 2023 Plan. As of March 20, 2026, there were 905,527 shares of Class A Common Stock available for issuance under the 2023 Plan. In addition, the Company has experienced significant dilution in its Class A Common Stock as a result of its recent financing transactions. As a result, the Company is requesting the approval of 6,000,000 additional shares of Class A Common Stock be authorized for issuance under the 2023 Plan, which would bring the aggregate number of shares of Class A Common Stock available for issuance under the 2023 Plan to 10,000,000. The full pool of 10,000,000 shares would constitute (i) approximately 11.5% of our issued and outstanding shares of Class A Common Stock, (ii) approximately 8.8% of outstanding shares of Class A Common Stock on an adjusted basis if Pre-Funded Warrants (exercisable for nominal consideration of $0.0001 per share) are included as outstanding shares of Class A Common Stock, or (iii) approximately 3.8% of our fully diluted shares of Class A Common Stock.
Without shares available under the Plan, we may not be able to offer competitive compensation to existing employees and qualified candidates, which could prevent us from successfully attracting, motivating and retaining highly skilled employees.
Description of the Plan
The following paragraphs provide a summary of the principal features of the 2023 Plan and its operation. However, this summary is not a complete description of all of the provisions of the 2023 Plan and is qualified in its entirety by the specific language of the 2023 Plan, which is included as Exhibit 10.3 to our Annual Report on Form 10-K for the year ending December 31, 2025.
Purpose of the 2023 Plan
The purpose of the 2023 Plan is to attract and retain the best available personnel for positions of substantial responsibility with Envoy Medical and any parent or subsidiary of Envoy Medical, to provide additional incentive to eligible employees, directors, and consultants, and to promote the success of the Envoy Medical business. These incentives may be provided through the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other awards as the administrator of the 2023 Plan may determine.
Eligibility
The 2023 Plan permits the grant of incentive stock options, within the meaning of Section 422 of the Code, to Envoy Medical’s employees and any of its parent and subsidiary corporations’ employees, and the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance awards and other awards to employees, directors and consultants of Envoy Medical and its parents or subsidiaries. As of December 31, 2025, Envoy Medical and its subsidiaries had approximately 45 employees, 30 independent contractors and consultants, and 5 non-employee directors who are eligible for equity compensation.
Authorized Shares; Adjustments
Subject to the adjustment provisions contained in the 2023 Plan (e.g. for stock splits and combinations), a total of 4,000,000 shares of Class A Common Stock are currently reserved for issuance pursuant to the 2023 Plan. If the Plan Amendment is approved, an additional 6,000,000 shares of Class A Common Stock will be authorized for issuance under the 2023 Plan.
Shares issued under the 2023 Plan will come from the pool of authorized but unissued or re-acquired shares of Class A Common Stock. Shares subject to awards granted under the 2023 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for
13
issuance under the 2023 Plan. Additionally, shares issued pursuant to awards under the 2023 Plan that Envoy Medical repurchases or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant under the 2023 Plan.
If any dividend or other distribution (whether in cash, shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of shares or other securities of Envoy Medical, or other change in the corporate structure of Envoy Medical affecting the shares occurs (other than any ordinary dividends or other ordinary distributions), the administrator of the 2023 Plan, to prevent diminution or enlargement of the benefits or potential benefits intended to be provided under the 2023 Plan, will adjust the number and class of shares that may be delivered under the 2023 Plan; the number, class, and price of shares covered by each outstanding award; and the numerical share limits contained in the 2023 Plan.
Plan Administration
The Board has appointed the Compensation Committee as administrator of the Plan. The administrator may also delegate to one or more of Envoy Medical’s officers the authority to (1) designate employees (other than officers) to receive specified awards, and (2) determine the number of shares subject to such awards.
In addition, to the extent it is desirable to qualify transactions under the 2023 Plan as exempt under Rule 16b-3 of the Exchange Act, such transactions will be structured to satisfy the requirements for exemption under Rule 16b-3. Subject to the provisions of the 2023 Plan, the administrator has the power to administer the 2023 Plan and make all determinations deemed necessary or advisable for administering the 2023 Plan, including, but not limited to, the power to determine the fair market value of Class A Common Stock, select the service providers to whom awards may be granted, determine the number of shares or dollar amounts covered by each award, approve forms of award agreements for use under the 2023 Plan, determine the terms and conditions of awards (including, but not limited to, the exercise price, the time or times at which awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe and interpret the terms of the 2023 Plan and awards granted under it, prescribe, amend and rescind rules and regulations relating to the 2023 Plan, including creating sub-plans, modify or amend each award, and allow a participant to defer the receipt of payment of cash or the delivery of shares that otherwise would be due to such participant under an award. In addition, subject to the terms of the 2023 Plan, the administrator also has the power to modify outstanding awards under the 2023 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel and re-grant any outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under GAAP, with the consent of any materially adversely affected participant. The administrator’s decisions, interpretations and other actions are final and binding on all participants and will be given the maximum deference permitted by applicable law.
Types of Awards
The 2023 Plan provides for the grant of stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance awards and other awards. A brief description of each award type follows.
Stock Options
Incentive stock options and nonqualified stock options may be granted under the 2023 Plan pursuant to stock option agreements adopted by the administrator. A stock option entitles a participant to purchase a specified number of shares of Class A Common Stock during a specified term at an exercise price. The per share exercise price of options granted under the 2023 Plan generally must be equal to at least 100% of the fair market value of a share of Class A Common Stock on the date of grant. The term of an option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of Envoy Medical’s (or any of its parent’s or subsidiary’s) outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the per share exercise price must equal at least 110% of the fair market value of a share of Class A Common Stock on the grant date. The administrator will determine the methods of payment of the exercise price of an option, which may include (1) cash, check, bank draft or money order, (2) the tender of shares of Class A Common Stock previously owned by the optionholder, (3) a broker-assisted cashless exercise, (4) a net exercise of the option if it is an nonqualified stock option, and (5) other types of consideration permitted by applicable law. After the cessation of service of an employee,
14
director or consultant, he or she may exercise his or her option for the period of time stated in his or her option agreement. In the absence of a specified time in an award agreement, if such cessation is due to death or disability, the option will remain exercisable for 12 months following the cessation of service. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months following the cessation of service. An option, however, may not be exercised later than the expiration of its term. Subject to the provisions of the 2023 Plan, the administrator determines the terms of options. Until shares are issued under an option, the participant will not have any right to vote or receive dividends or have any other rights as a stockholder with respect to such shares, and no adjustment will be made for a dividend or other right for which the record date is before the date such shares are issued, except as provided in the 2023 Plan, as summarized further above.
Stock Appreciation Rights
Stock appreciation rights may be granted under the 2023 Plan. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of Class A Common Stock between the exercise date and the date of grant. The term of a stock appreciation right may not exceed ten years. After the cessation of service of an employee, director or consultant, he or she may exercise his or her stock appreciation rights for the period of time stated in his or her stock appreciation rights agreement. In the absence of a specified time in an award agreement, if such cessation is due to death or disability, the stock appreciation rights will remain exercisable for six months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable for three months following the cessation of service. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of the 2023 Plan, the administrator determines the terms of stock appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of Class A Common Stock, or a combination of both, except that the per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right generally will be no less than 100% of the fair market value per share on the date of grant. Until shares are issued under a stock appreciation right, the participant will not have any right to vote or receive dividends or have any other rights as a stockholder with respect to such shares, and no adjustment will be made for a dividend or other right for which the record date is before the date such shares are issued, except as provided in the 2023 Plan, as summarized further above.
Restricted Stock
Restricted stock may be granted under the 2023 Plan. Restricted stock awards are grants of shares of Class A Common Stock that may have vesting requirements as specified in the restricted stock award agreements adopted by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee, director or consultant and, subject to the provisions of the 2023 Plan, will determine the terms and conditions of such awards. The administrator may impose whatever restrictions on transferability, forfeiture provisions or other restrictions or vesting conditions (if any) it determines to be appropriate (for example, the administrator may set restrictions based on the achievement of specific performance goals or continued service to us). The administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to Envoy Medical or any other form of legal consideration. Class A Common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in Envoy Medical’s favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the administrator. Recipients of restricted stock awards generally will have voting rights and rights to dividends and other distributions with respect to such shares upon grant, unless the administrator provides otherwise. If such dividends or distributions are paid in shares, the shares will be subject to the same restrictions on transferability and forfeitability as the share of restricted stock with respect to which they were paid. Shares of restricted stock that do not vest are subject to the right of repurchase or forfeiture.
Restricted Stock Units
Restricted stock units may be granted under the 2023 Plan. Each restricted stock unit is a bookkeeping entry representing an amount equal to the fair market value of one share of Class A Common Stock. Subject to the provisions of the 2023 Plan, the administrator determines the terms and conditions of restricted stock units, including any vesting
15
criteria and the form and timing of payment, as specified in the restricted stock unit award agreements adopted by the administrator. The administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, shares, or a combination of both. Restricted stock unit awards may be granted in consideration for any form of legal consideration. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant’s cessation of continuous service for any reason. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed.
Performance Awards
Performance awards may be granted under the 2023 Plan. Performance awards are awards that may be earned in whole or in part upon the attainment of performance goals or other vesting criteria that the administrator may determine and may be denominated in cash or stock. Subject to the terms and conditions of the 2023 Plan, the administrator can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of certain pre-established performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, Class A Common Stock. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed.
Other Awards
The administrator may grant other awards based in whole or in part by reference to Class A Common Stock. The administrator will set the number of shares under the award and all other terms and conditions of such awards.
Non-Employee Director Eligibility
All outside (non-employee) directors will be eligible to receive all types of awards (except for incentive stock options) under the 2023 Plan.
Non-Transferability of Awards
Unless the administrator provides otherwise, the 2023 Plan generally does not allow for the transfer of awards other than by will or the laws of descent and distribution, and only the recipient of an award may exercise an award during his or her lifetime. If the administrator makes an award transferable, such award will contain such additional terms and conditions as the administrator deems appropriate.
Dissolution or Liquidation
Unless otherwise provided in the award agreements, if there is a proposed liquidation or dissolution of Envoy Medical, all awards, to the extent that they have not been previously exercised or vested, will terminate immediately before the consummation of such event. However, the Board may determine to cause some or all awards to become fully vested or exercisable before the dissolution or liquidation.
Corporate Transaction
In the event of a corporate transaction, the outstanding awards may be treated in accordance with one or more of the following methods as determined by the Board in its sole discretion: (i) settle such awards for an amount of cash or securities, where in the case of stock options and stock appreciation rights, the value of such amount will be equal to the in-the-money spread value of such awards; (ii) provide for the assumption or substitution of such awards with new awards that will substantially preserve the applicable terms of any affected awards previously granted under the 2023 Plan; (iii) modify the terms of such awards to add events, conditions or circumstances (including termination of employment or service within a specified period after a corporate transaction) upon which the vesting of such awards will accelerate; (iv) deem any performance conditions satisfied at target, maximum or actual performance through closing or provide for the performance conditions to continue after closing or (v) provide that for a period of at least 20 days prior to the corporate transaction, any stock options or stock appreciation rights that would not otherwise become exercisable prior to the corporate transaction will be exercisable and that any stock options or stock appreciation rights not exercised prior to the consummation of the corporate transaction will terminate after the closing.
16
Under the 2023 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of Envoy Medical’s assets, (2) a sale or other disposition of at least 50% of the total combined voting power of Envoy Medical’s outstanding securities, (3) a merger, consolidation or similar transaction following which Envoy Medical is not the surviving corporation, (4) a merger, consolidation or similar transaction following which Envoy Medical is the surviving corporation but (x) the shares of Class A Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction or (y) the securities possessing more than 50% of the total combined voting power of Envoy Medical’s outstanding securities are transferred to a person or persons different from those who held such securities prior to such merger or (5) a complete liquidation or dissolution of Envoy Medical.
Forfeiture and Clawback
Awards will be subject to any clawback policy Envoy Medical is required to adopt pursuant to the listing standards of any national securities exchange or association on which Envoy Medical securities are listed or as is otherwise required by applicable laws. The administrator also may specify in an award agreement that the participant’s rights, payments and benefits with respect to an award will be subject to reduction, cancellation, forfeiture, recoupment, reimbursement, or reacquisition upon the occurrence of certain specified events. The administrator may require a participant to forfeit or return to Envoy Medical or reimburse Envoy Medical for all or a portion of the award and any amounts paid under the award in order to comply with any clawback policy of Envoy Medical as described in the first sentence of this paragraph or with applicable laws.
Amendment or Termination
The 2023 Plan will continue in effect until terminated by the administrator. However, no incentive stock options may be granted after the ten-year anniversary of the adoption of the 2023 Plan by the Board in September 2023. In addition, the administrator will have the authority to amend, suspend, or terminate the 2023 Plan or any part of the 2023 Plan, at any time and for any reason, but such action generally may not materially impair the rights of any participant without his or her written consent. No awards may be granted under the 2023 Plan while it is suspended or after it is terminated.
Summary of U.S. Federal Income Tax Consequences
The following summary is intended only as a general guide to the U.S. federal income tax consequences of participation in the 2023 Plan. The summary is based on existing U.S. laws and regulations, and there can be no assurance that those laws and regulations will not change in the future. The summary does not purport to be complete and does not discuss the tax consequences upon a participant’s death, or the provisions of the income tax laws of any municipality, state or non-U.S. jurisdiction in which the participant may reside. As a result, tax consequences for any particular participant may vary based on individual circumstances. This summary is not intended as tax advice to participants, and participants should consult their own tax advisors.
Incentive Stock Options
A participant generally recognizes no taxable income for ordinary income tax purposes as a result of the grant or exercise of an option that qualifies as an incentive stock option under Section 422 of the Code. If a participant exercises the option and then later sells or otherwise disposes of the shares acquired through the exercise of the option after both the two-year anniversary of the date the option was granted and the one-year anniversary of the date of exercise of the option, the participant will recognize a capital gain or loss equal to the difference between the sale price of the shares and the exercise price.
However, if the participant disposes of such shares either on or before the two-year anniversary of the date of grant or on or before the one-year anniversary of the date of exercise of the option (a “disqualifying disposition”), any gain up to the excess of the fair market value of the shares on the date of exercise over the exercise price generally will be taxed as ordinary income, unless the shares are disposed of in a transaction in which the participant would not recognize a gain (such as a gift). Any gain in excess of that amount will be a capital gain. If a loss is recognized with respect to the share disposition, there will be no ordinary income, and such loss will be a capital loss.
17
For purposes of the alternative minimum tax, the difference between the option exercise price and the fair market value of the shares on the date of exercise of the option is treated as an adjustment item in computing the participant’s alternative minimum taxable income in the year of exercise (unless the shares are disposed of in the same year as the option exercise). In addition, special alternative minimum tax rules may apply to certain subsequent disqualifying dispositions of the shares or provide certain basis adjustments or tax credits.
Nonstatutory Stock Options
A participant generally recognizes no taxable income for ordinary income tax purposes as a result of the grant of such an option. However, upon exercising the option, the participant generally recognizes ordinary income equal to the amount that the fair market value of the shares on such date exceeds the exercise price. If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes. Upon the sale or other disposition of the shares acquired by the exercise of a nonstatutory stock option, any gain or loss (based on the difference between the sale price and the fair market value on the exercise date) will be taxed as capital gain or loss.
Stock Appreciation Rights
In general, no taxable income for ordinary income tax purposes is reportable when a stock appreciation right is granted to a participant. Upon exercise, the participant generally will recognize ordinary income in an amount equal to the fair market value of any shares received. Any additional gain or loss recognized upon any later disposition of the shares would be capital gain or loss.
Restricted Stock Awards
A participant acquiring shares of restricted stock generally will recognize ordinary income equal to the fair market value of the shares on the vesting date. If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes. The participant, pursuant to Section 83(b) of the Code, may elect to accelerate the ordinary income tax event to the date of acquisition of the shares by filing an election with the IRS generally no later than thirty days after the date the shares are acquired. Upon the sale of shares acquired pursuant to a restricted stock award, any gain or loss, based on the difference between the sale price and the fair market value on the date the ordinary income tax event occurs, will be taxed as capital gain or loss.
Restricted Stock Units and Performance Awards
There generally are no immediate tax consequences of receiving an award of restricted stock units or a performance award. A participant who is granted restricted stock units or performance awards generally will be required to recognize ordinary income in an amount equal to the fair market value of shares issued to such participant at the time of settlement of the award upon vesting. If the participant is an employee, generally such ordinary income is subject to income tax withholding and certain employment tax withholdings. Any additional gain or loss recognized upon any later disposition of any shares received would be capital gain or loss.
Section 409A
Section 409A of the Code (“Section 409A”) provides certain requirements for non-qualified deferred compensation arrangements with respect to an individual’s deferral and distribution elections and permissible distribution events. Awards with a deferral feature granted under the 2023 Plan to a participant subject to U.S. income tax will be subject to the requirements of Section 409A. If an award is subject to and fails to satisfy the requirements of Section 409A, the recipient of that award may recognize ordinary income on the amounts deferred under the award, to the extent vested, which may be prior to when the compensation is actually or constructively received. Also, if an award that is subject to Section 409A fails to comply with the requirements of Section 409A, Section 409A imposes an additional 20% federal income tax on compensation recognized as ordinary income, as well as interest on such deferred compensation.
THE FOREGOING IS ONLY A SUMMARY OF THE EFFECT OF U.S. FEDERAL INCOME TAXATION UPON PARTICIPANTS AND ENVOY MEDICAL WITH RESPECT TO AWARDS UNDER THE 2023 PLAN. IT DOES NOT PURPORT TO BE COMPLETE AND DOES NOT DISCUSS THE IMPACT OF EMPLOYMENT OR OTHER TAX REQUIREMENTS, THE TAX CONSEQUENCES OF A PARTICIPANT’S DEATH, OR THE PROVISIONS OF THE INCOME TAX LAWS OF ANY MUNICIPALITY, STATE, OR NON-U.S. JURISDICTION IN WHICH THE PARTICIPANT MAY RESIDE.
18
New Plan Benefits
The awards, if any, that will be made to eligible persons under the 2023 Plan are subject to the discretion of the Compensation Committee and, therefore, we cannot currently determine the benefits or number of shares subject to awards that may be granted in the future to our executive officers, employees and directors under the 2023 Plan. Therefore, a New Plan Benefits Table has not been provided.
Registration with the SEC
The 4,000,000 shares of Class A Common Stock currently authorized for issuance under the 2023 Plan have been registered through a Registration Statement on Form S-8. We will file a new Registration Statement on Form S-8 to register the additionally authorized 6,000,000 shares of Class A Common Stock if the amendment of the 2023 Plan is approved.
Vote Required
Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of Envoy Medical represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve the amendment to the 2023 Plan.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE APPROVAL OF THE PLAN AMENDMENT TO AUTHORIZE AN ADDITIONAL 6,000,000 SHARES OF CLASS A COMMON STOCK UNDER THE 2023 PLAN.
19
PROPOSAL NO. 5
AMENDMENT TO ENVOY MEDICAL INC.
2023 EMPLOYEE STOCK PURCHASE PLAN
The Board has approved, subject to stockholder approval, an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan (the “ESPP”), to increase the number of shares of Class A Common Stock reserved for issuance under the ESPP by 1,200,000 shares.
The ESPP originally went into effect when Envoy Medical became a public company through a business combination transaction in September 2023. The ESPP provides eligible employees an opportunity to purchase shares of Class A Common Stock at a discount through accumulated contributions of their earned compensation. The Board has determined that offering an employee stock purchase plan is important to the ability of Envoy Medical to compete for talent. If the Stockholders do not approve the amendment to the ESPP, we will run out of shares available under the ESPP in approximately May 2026. Without shares available under the ESPP, we may not be able to offer competitive compensation to existing employees and qualified candidates, which could prevent us from successfully attracting, motivating and retaining highly skilled employees.
Proposed Amendment to the ESPP
The Compensation Committee has recommended and the Board of Directors has approved, subject to stockholder approval, an amendment to the ESPP to increase the number of shares authorized for issuance under the ESPP by 1,200,000 shares, which amount is intended to cover purchases for approximately two years. However, the number of shares purchased on each May 31 and November 30 purchase date is determined based on the amount of salary withheld from eligible employees divided by 85% of the market price of our Class A Common Stock on the first or last day of the applicable purchase period, whichever is lower, which means that the number of shares purchased will vary based on the market price of our Class A Common Stock. If the market price of our Class A Common Stock increases or decreases significantly, the number of shares of Class A Common Stock would last for a period that is, respectively, significantly longer or shorter than anticipated.
Summary of the ESPP
The following is a summary of the principal features of the ESPP and its operation. This summary does not contain all the terms and conditions of the ESPP and is qualified in its entirety by the specific language of the ESPP, which is included as Exhibit 10.4 to our Annual Report on Form 10-K for the year ended December 31, 2025.
Purpose
The purpose of the ESPP is to provide eligible employees with an opportunity to purchase shares of the Class A Common Stock through accumulated contributions, which generally will be made through payroll deductions. The ESPP will permit the administrator of the ESPP to grant purchase rights that qualify for preferential tax treatment under Section 423 of the Code. In addition, the ESPP will authorize the grant of purchase rights that do not qualify under Section 423 of the Code pursuant to rules, procedures or sub-plans adopted by the administrator that are designed to achieve desired tax or other objectives.
Shares Available for Issuance; Adjustments
Subject to adjustment upon certain changes in our capitalization as described in the ESPP, the maximum number of shares of Class A Common Stock that are authorized for issuance under the ESPP is currently 300,000 shares and would increase to an aggregate of 1,500,000 shares if the proposed amendment to the ESPP is approved. We are unable to determine how long this share reserve may last because the number of shares that will be issued in any purchase period depends on a variety of factors that cannot be predicted with certainty, including, for example, the number of employees who elect to participate in the ESPP, the level of contributions made by participants, and the market price of our Class A Common Stock.
The ESPP provides that in the event that any dividend or other distribution (whether in the form of cash, shares, other securities or other property), recapitalization, stock split, reverse stock split, stock dividend, combination, reclassification, reorganization, merger, consolidation, acquisition of property or stock, split-up, spin-off, combination, liquidation, reclassification, repurchase or exchange of our Class A Common Stock or other securities of Envoy
20
Medical or other change in Envoy Medical’s corporate structure affecting the Class A Common Stock occurs (other than any ordinary dividends or other ordinary distributions), to prevent diminution or enlargement of the benefits or potential benefits intended to be provided under the ESPP, the administrator will make adjustments to (i) the maximum number of securities issuable under the ESPP and (ii) the number of securities subject to each outstanding purchase right and the purchase price payable per share thereunder.
Administration
The Compensation Committee has been delegated authority to administer the ESPP. The administrator will have full and exclusive discretionary authority to construe, interpret and apply the terms of the ESPP, delegate ministerial duties to any of Envoy Medical’s employees, designate separate offerings under the ESPP, designate any subsidiaries of Envoy Medical as participating in the ESPP, determine eligibility, adjudicate all disputed claims filed under the ESPP and establish procedures that it deems necessary or advisable for the administration of the ESPP. The administrator has full authority to adopt such rules and procedures as it may deem necessary for the proper plan administration and to interpret the provisions of the ESPP, including the authority to determine whether the purchase price for any purchase period will be equal to the lower of: (1) 85% of the fair market value of a share of Class A Common Stock on the date of purchase or (2) 85% of the fair market value of a share of Class A Common Stock on the first day of the offering period or the purchase date. The administrator’s findings, decisions and determinations will be final and binding on all participants to the maximum extent permitted by law.
Eligibility
Generally, any employees of Envoy Medical are eligible to participate in the ESPP if they are customarily employed by Envoy Medical or any of its participating subsidiaries for at least 20 hours per week and more than five months in any calendar year. However, unless otherwise determined by the administrator prior to an offering date, an employee is ineligible to participate in the ESPP or the relevant offering period if that employee: (a) has not completed for such continuous period as the administrator may require (which period must be less than two years), (b) customarily works not more than 20 hours per week, (c) customarily works not more than five months per calendar year, (d) is a citizen or resident of a country other than the United States and the laws of the jurisdiction in which the employee is a citizen or resident prohibit participation or if complying with the laws of the foreign jurisdiction would cause the ESPP to violate applicable U.S. tax law. In addition, an employee may not be granted an option to purchase stock under the ESPP if the employee (a) immediately after the grant, would own stock and/or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of capital stock of Envoy Medical or any parent or subsidiary of Envoy Medical; or (b) holds rights to purchase stock under all of Envoy Medical’s employee stock purchase plans that accrue at a rate that exceeds $25,000 worth of stock determined at the time such option is granted, for each calendar year during which his or her right to purchase shares is outstanding at any time. As of the date of December 31, 2025, Envoy Medical had approximately 45 employees eligible to participate in the ESPP.
Participants may end their participation at any time during an offering period and will be paid their accrued contributions that have not yet been used to purchase shares of Class A Common Stock. Participation ends automatically upon termination of employment with Envoy Medical (or its participating subsidiaries).
Offering Periods
The ESPP provides two six-month offering periods each year, running from June 1 to November 30 and December 1 to May 31, respectively. The administrator may alter the duration of future offering periods in advance without stockholder approval. Each participant is granted a separate purchase right to purchase shares of Class A Common Stock for each offering period in which he or she participates. Purchase rights under the ESPP are granted on the start date of each offering period and are automatically exercised on the last day of the offering period. Each purchase right entitles the participant to purchase the whole number of shares of Class A Common Stock obtained by dividing the participant’s payroll deductions for the offering period by the purchase price in effect for such period.
Contributions
Each participant in the ESPP may authorize periodic payroll deductions that may not exceed 15% of his or her compensation, which is defined in the ESPP to include the regular base salary, unless the plan administrator determines otherwise. Unless otherwise determined by the plan administrator, compensation will not include overtime, bonuses,
21
annual awards, other incentive payments, reimbursements or other expense allowances, loan forgiveness, fringe benefits, moving expenses, deferred compensation, or contributions (other than contributions under a 401(k) or cafeteria plan). A participant may reduce his or her rate of payroll deductions during an offering period, subject to the rules set by the plan administrator.
On the last day of each offering period, the accumulated payroll deductions of each participant will be automatically applied to the purchase shares of Class A Common Stock at the purchase price in effect for that period.
Exercise of Purchase Right
The purchase price per share at which Class A Common Stock is purchased on the participant’s behalf for each offering period is equal to either (1) 85% of the fair market value of a share of Class A Common Stock on the date of purchase or (2) 85% of the fair market value of a share of Class A Common Stock on the first day of the offering period or the purchase date, whichever is lower. Unless determined otherwise by the administrator, the purchase price is equal to 85% of the fair market value of a share of Class A Common Stock on the first day of the offering period or the purchase date, whichever is lower. Until shares of Class A Common Stock are issued (as evidenced by the appropriate entry on our books or the books of a duly authorized transfer agent of ours) to a participant, the participant will have only rights of an unsecured creditor with respect to such shares, and no right to vote or receive dividends or any other rights as a stockholder with respect to such shares.
Termination of Participation
Participation in the ESPP generally will terminate when a participating employee’s employment with Envoy Medical or a participating subsidiary ceases for any reason, the employee withdraws from the ESPP or Envoy Medical terminates or amends the ESPP such that the employee is no longer eligible to participate. An employee may withdraw his or her participation in the ESPP at any time in accordance with the procedures set forth in the ESPP, and prior to any applicable deadline specified by the administrator. Upon withdrawal from the ESPP, generally the employee will receive all amounts credited to his or her account without interest (unless otherwise required under applicable law) and his or her payroll withholdings or contributions under the ESPP will cease.
Non-Transferability
A participant is not permitted to transfer the contributions credited to his or her ESPP account or rights granted under the ESPP, other than by will or the laws of descent and distribution.
Corporate Transaction
In the event of a corporate transaction during an offering period, all outstanding purchase rights shall be assumed by the successor corporation (or a parent or subsidiary thereof), unless the administrator determines, in its sole discretion, to shorten the offering period then in-effect to a new purchase date. If the administrator shortens the offering period then in progress to a new purchase date, the plan administrator will provide notice to each participant that (i) his or her purchase right will be automatically exercised on the new purchase date or (ii) Envoy Medical will pay to him or her, on the new purchase date, cash, cash equivalents, or property as determined by the plan administrator that is equal to the difference in the fair market value of the shares of Class A Common Stock covered by his or her purchase right and the purchase price due had the purchase right been automatically exercised on the new purchase date.
Effective Date; Amendment; Termination
The ESPP became effective upon stockholder approval in September 2023. The administrator will have the authority to modify, amend, suspend or terminate the ESPP at any time. To the extent required by Section 423 of the Internal Revenue Code (or any successor rule or provision or any other applicable law), Envoy Medical will seek stockholder approval of amendments in such a manner and to such a degree as so required. If the ESPP is terminated, the administrator may elect to terminate all outstanding offering periods either immediately or upon the next exercise date, or may elect to permit offering periods to expire in accordance with their terms. If the offering periods are terminated prior to expiration, all amounts then credited to participants’ accounts that have not been used to purchase shares will be returned to the participants.
22
Under the ESPP, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of Envoy Medical’s assets, (2) a sale or other disposition of at least 50% of the total combined voting power of Envoy Medical’s outstanding securities, (3) a merger, consolidation or similar transaction following which Envoy Medical is not the surviving corporation, (4) a merger, consolidation or similar transaction following which Envoy Medical is the surviving corporation but (x) the shares of Class A Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction or (y) the securities possessing more than 50% of the total combined voting power of Envoy Medical’s outstanding securities are transferred to a person or persons different from those who held such securities prior to such merger or (5) a complete liquidation or dissolution of Envoy Medical.
Summary of U.S. Federal Income Tax Consequences
The following summary is intended only as a general guide to the U.S. federal income tax consequences of participation in the ESPP. The summary is based on existing U.S. laws and regulations, and there can be no assurance that those laws and regulations will not change in the future. The summary does not purport to be complete and does not discuss the tax consequences upon a participant’s death, or the provisions of the income tax laws of any municipality, state or non-U.S. jurisdiction to which the participant may be subject. As a result, tax consequences for any particular participant may vary based on individual circumstances. This summary is not intended as tax advice to participants, and participants should consult their own tax advisors.
The ESPP is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Code. Under an employee stock purchase plan that so qualifies, no taxable income will be recognized by a participant, and no deductions will be allowable to Envoy Medical, upon either the grant or the exercise of the purchase rights. Taxable income will not be recognized until there is a sale or other disposition of the shares of Class A Common Stock acquired under the ESPP or in the event of the participant’s death while still owning the purchased shares of Class A Common Stock.
If the participant sells or otherwise disposes of the purchased shares of Class A Common Stock within two years after the start date of the offering period in which the shares of Class A Common Stock were acquired or within one year after the date of purchase of those shares of Class A Common Stock, then the participant generally will recognize ordinary income in the year of sale or disposition equal to the amount by which the fair market value of the shares of Class A Common Stock on the purchase date exceeded the purchase price paid for those shares of Class A Common Stock, and Envoy Medical will be entitled to an income tax deduction equal in amount to such excess, for the taxable year in which such disposition occurs. The amount of this ordinary income will be added to the participant’s basis in the shares of Class A Common Stock, and any resulting gain or loss recognized upon the sale or disposition will be a capital gain or loss. If the shares of Class A Common Stock have been held for more than one year since the date of purchase, the gain or loss will be long-term capital gain or loss.
If the participant sells or disposes of the purchased shares of Class A Common Stock more than two years after the start date of the offering period in which the shares of Class A Common Stock were acquired and more than one year after the date of purchase of those shares of Class A Common Stock, then the participant generally will recognize ordinary income in the year of sale or disposition equal to the lesser of (a) the amount by which the fair market value of the shares of Class A Common Stock on the sale or disposition date exceeded the purchase price paid for those shares of Class A Common Stock, or (b) 15% of the fair market value of the shares of Class A Common Stock on the start date of that offering period. Any additional gain upon the disposition will be taxed as a long-term capital gain. Alternatively, if the fair market value of the shares of Class A Common Stock on the date of the sale or disposition is less than the purchase price, there will be no ordinary income and any loss recognized will be a long-term capital loss. We will not be entitled to an income tax deduction with respect to such disposition.
New Plan Benefits
Participation in the ESPP is voluntary and the number of shares of Class A Common Stock that will be purchased in any given year or offering period under the ESPP is dependent on various factors such as each eligible employee’s election to participate, the amount of his or her eligible compensation, and his or her determination as to the portion of his or her eligible compensation to contribute to the ESPP. Further, such number of shares of Class A Common Stock that may be purchased under the ESPP is determined, in part, by the price of the shares of Class A Common Stock on the first day of each offering period and applicable exercise date of each purchase period. Accordingly, the actual
23
number of shares of Class A Common Stock that would be purchased by any individual under the ESPP in the future is not determinable. We have not previously sponsored an employee stock purchase plan, and, therefore, the number of shares of Class A Common Stock which would have been received by or allocated to Envoy Medical named executive officers, all current executive officers as a group, and all other current employees who may participate in the ESPP as a group are not determinable. Non-employee directors are not eligible to participate in the ESPP. As of March 20, 2026, the closing price of a share of Class A Common Stock was $[0.70].
Equity Compensation Plan Information
As of December 31, 2025, Envoy Medical had 54,751 shares of Class A Common Stock available for issuance under the ESPP.
Registration with the SEC
The issuance of the 300,000 shares of Class A Common Stock currently registered for issuance under the ESPP has been registered by Envoy Medical under a Registration Statement on Form S-8. If the amendment is approved, the issuance of the additional 1,200,000 shares of Class A Common Stock authorized for issuance under the ESPP will be registered by Envoy Medical under a registration statement on Form S-8.
Vote Required
Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of Envoy Medical represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve the amendment to the ESPP.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE APPROVAL OF THE PLAN AMENDMENT TO AUTHORIZE AN ADDITIONAL 1,200,000 SHARES OF CLASS A COMMON STOCK UNDER THE ESPP.
24
PROPOSAL NO. 6
issuance Proposal
We are seeking stockholder approval, for purposes of complying with Nasdaq Listing Rule 5635(d), for (i) the exercisability of Milestone Warrants (as defined below) to purchase up to an aggregate of 120,000,000 shares of Class A Common Stock (the “Common Warrant Shares”); (ii) the exercisability of Placement Agent Warrants (as defined below) to purchase up to 3,750,000 shares of Class A Common Stock (the Placement Agent Warrants and Milestone Warrants, together, are referred to as the “Common Warrants”); and (iii) the issuance of an aggregate of 123,750,000 shares of Class A Common Stock issuable upon exercise of such Common Warrants, which Common Warrants were issued in our best efforts public offering that closed on February 12, 2026.
Background
On February 12, 2026, the Company completed a best efforts public offering (the “February 2026 Offering”) of an aggregate of (i) 47,946,150 shares (the “Shares”) of Class A Common Stock, (ii) 27,053,850 pre-funded warrants (the “Issued Pre-Funded Warrants”) to purchase 27,053,850 shares of Class A Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Class A Common Stock and/or pre-funded warrants (the “Series A-1 Warrants”), and (iv) 75,000,000 Series A-2 Warrants to purchase 75,000,000 shares of Common Stock and/or pre-funded warrants (the “Series A-2 Warrants” and, together with the Series A-1 Warrants, the “Milestone Warrants”). Investors in the Offering received, for each Share purchased (or Issued Pre-Funded Warrant purchased in lieu thereof), accompanying Common Warrants in the amount of six-tenths (0.6) of a Series A-1 Warrant and one Series A-2 Warrant. The purchase price for the February 2026 Offering was $0.40 per Share (or $0.3999 per Issued Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants. Pre-funded warrants are issuable to investors who would otherwise exceed an ownership cap equal to 4.99% or 9.99% of outstanding shares of Class A Common Stock, with the applicable cap selected by each investor.
The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date, or (ii) 30 days from the Company’s achievement of Milestone 1 (defined below). The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date, or (ii) 30 days from the Company’s achievement of Milestone 2 (defined below). For purposes of the Series A-1 Warrants and Series A-2 Warrants, respectively, “Milestone 1” means the Company’s public announcement that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration (the “FDA”) for its Acclaim CI device, and “Milestone 2” means the Company’s public announcement that the FDA has approved the marketing of its Acclaim CI device.
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the Offering pursuant to an Engagement Letter, dated September 17, 2025, as amended (the “Engagement Letter”). Pursuant to the terms of the Engagement Letter, the Company issued to designees of Wainwright warrants (the “Placement Agent Warrants”) to purchase up to 3,750,000 shares of Common Stock, which represents 5% of the aggregate number of Shares and Pre-Funded Warrants issued in the Offering, with an exercise price of $0.50 per share (representing 125% of the sale price of Shares and accompanying Milestone Warrants in the Offering) and a termination date that will be the earliest of (i) the 24-month anniversary of the date of Stockholder Approval, (ii) 30 days following the occurrence of Milestone 1, and (iii) five years from the commencement of the sales pursuant to the Offering.
Each Milestone Warrant has an exercise price of $0.40 per share (or $0.3999 per pre-funded warrant in lieu thereof) and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants, which would be the date of approval of the Issuance Approval, if approved. The Company agreed to seek Stockholder Approval no later than 90 days after the consummation of Offering, which it is doing at the Annual Meeting through the Issuance Proposal. If the Issuance Proposal is not approved, the Company has agreed to call a stockholder meeting every 90 days thereafter until the earlier of the date it obtains Stockholder Approval or the date the Common Warrants are no longer outstanding. The exercise price of the Common Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.
25
Effect of the Issuance of the Common Warrants and the Warrant Shares
The issuance of the Warrant Shares upon exercise of the Common Warrants would result in substantial increase in the number of shares of Class A Common Stock outstanding, and our stockholders would incur dilution of their percentage ownership to the extent that the holders thereof exercise their warrants.
Reasons for Nasdaq Stockholder Approval
Nasdaq Listing Rule 5635(d) — 20% Threshold
Our Class A Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) and trades under the ticker symbol “COCH.” Nasdaq Listing Rule 5635(d) requires stockholder approval of certain transactions involving greater than 20% of the outstanding common stock or voting power of the issuer prior to the offering. The issuance of the Common Warrants in the Offering implicated Nasdaq Listing Rule 5635(d), which requires stockholder approval prior to the issuance of securities in connection with a transaction other than a public offering that meets certain requirements.
In order to comply with Nasdaq Listing Rule 5635(d), the Common Warrants are not exercisable until Stockholder Approval is obtained.
Potential Consequences if this Proposal is Not Approved
The Board of Directors is not seeking the approval of our stockholders to authorize our entry into or consummation of the transactions that constitute the Offering, as the Offering has already been completed and the Common Warrants have already been issued. We are only asking for approval to allow the issuance of the shares underlying the Common Warrants upon exercise thereof.
The failure of our stockholders to approve this proposal will mean that we: (i) cannot permit the exercise of the Common Warrants and (ii) may incur substantial additional costs and expenses in continuing to seek Stockholder Approval.
The Common Warrants have initial exercise price of $0.40 per share. Accordingly, we would realize an aggregate of up to approximately $49.9 million in gross proceeds if all the Common Warrants were exercised based on such value. If the Common Warrants cannot be exercised, we will not receive any such proceeds, which could adversely impact our ability to fund our operations.
In connection with the Offering and the issuance of the Common Warrants, we agreed to seek stockholder approval every 90 days until our stockholders approve the issuance of the shares underlying the Common Warrants. We are required to seek such approval until such time as none of the Common Warrants are outstanding which could result in us seeking such approval every 90 days for five years. The costs and expenses associated with seeking such approval could materially adversely impact our ability to fund our operations, our long-term performance and our strategic goals.
Potential Adverse Effects of the Approval of this Proposal
If this proposal is approved, existing stockholders will suffer dilution in their ownership interests in the future upon the issuance of shares of Warrant Shares upon exercise of the Common Warrants. Assuming the full exercise of the Common Warrants 123,750,000 additional shares of Class A Common Stock will be outstanding, and the ownership interest of our existing stockholders would be correspondingly reduced. In addition, the sale into the public market of these shares could materially and adversely affect the market price of our Class A Common Stock.
Further Information
The terms of the Purchase Agreement and the Offering are only briefly summarized above. For further information, please refer to the form of Common Warrant, which was filed with the SEC as exhibits to our Current Report on Form 8-K, filed with the SEC on February 13, 2026 and is incorporated herein by reference. The discussion herein is qualified in its entirety by reference to the filed documents.
Stockholders are urged to carefully read these documents.
26
Interest of Certain Persons in the Issuance Proposal
As further described under the heading “Certain Relationships and Related Transactions — February 2026 Stock and Warrant Financing” certain executive officers, directors, and former directors of the Company. The following individuals purchased Shares and Common Warrants in the Offering on the same terms as the third-party investors, and such individuals will receive the benefit of being able to exercise their Common Warrants if the Issuance Proposal is approved:
• Brent Lucas, the Company’s Chief Executive Officer and a director, holds 100,000 Common Warrants;
• Robert Potashnick, our Interim Chief Financial Officer, holds 340,000 Common Warrants;
• Chuck R. Brynelsen, a director, holds 1,600,000 Common Warrants;
• Mona Patel, a director, holds 500,000 Common Warrants;
• Susan Kantor, a director, holds 153,840 Common Warrants;
• Glen A. Taylor, who served as a director through August 2025 and directly or indirectly owns approximately 37.8% of the outstanding shares of Class A Common Stock, holds 30,000,000 Common Warrants.
Voting Considerations
On September 4, 2025, the Company entered into a Voting and Warrant Extension Agreement (the “Voting and Extension Agreement”) with Mr. Taylor and certain entities controlled by Mr. Taylor (collectively, the “Taylor Parties”). The Voting and Extension Agreement provides, among other things that the Taylor Parties agree to vote any shares beneficially owned by the Taylor Parties in favor of any proposal required to be approved by the Company’s stockholders to ensure compliance with certain Nasdaq Listing Rules, provided that the proposal is unanimously approved and recommended by the Board. The Taylor Parties’ voting obligations will be in effect through December 31, 2028 and will be binding on any transferees of the Class A Common Stock.
This means that the Taylor Parties have agreed to vote all shares beneficially owned by the Taylor Parties in favor of this Issuance Proposal.
Vote Required
Assuming a quorum is present, the affirmative vote of a majority of the shares of Class A Common Stock of the Company represented at the Annual Meeting, either in person or by proxy, and entitled to vote is required to approve the Issuance Proposal.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE
STOCKHOLDERS VOTE FOR THE ISSUANCE PROPOSAL TO AUTHORIZE THE ISSUANCE OF 123,750,000 SHARES OF CLASS A COMMON STOCK UPON EXERCISE OF THE COMMON WARRANTS.
27
CORPORATE GOVERNANCE
The Board believes that adherence to good corporate governance principles is essential to running our business efficiently, to maintaining our integrity in the marketplace, and to ensuring that the Company is managed for the long-term benefit of our stockholders. The Board recognizes that maintaining and ensuring good corporate governance is a continuous process. The Board has adopted the Code of Business Conduct and Ethics of Envoy Medical, Inc. (the “Code of Ethics”) and a charter for each standing committee of the Board. The Code of Ethics and the Charters of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, as amended from time to time, are available on the Company’s website at ir.envoymedical.com/ and will be provided in printed form to any stockholder who requests them from us. Requests should be directed to Corporate Secretary, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110.
Board of Directors
Our Bylaws provide that the size of the Board will be determined from time to time by resolution of the Board. Under our Bylaws, the Board is divided into three classes, each of which director class is elected for staggered three-year terms. Each director serves until the director’s successor is elected, or until the earlier death, resignation or removal of the director. Our Bylaws provide that members of the Board will be elected by a plurality vote of our stockholders.
Director Independence
The Board has determined that each of Chuck R. Brynelsen, Michael Crowe, Susan J. Kantor, Mona Patel, and Janis Smith-Gomez qualifies as an independent director under the Nasdaq Listing Rules. In evaluating independence, the Board considered all relevant relationships affecting director independence.
Board Leadership Structure
The Board recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide effective oversight of management. Our Bylaws and Principles of Corporate Governance do not restrict the Board’s ability to combine or separate the positions of Chairman of the Board and Chief Executive Officer. The roles of Chair of the Board and Chief Executive Officer are held by different individuals. At this time, the Board believes that this structure provides an efficient and effective leadership model for our Company, facilitates efficient and open communication between our directors and management team, and helps to involve our other independent Board members in Board activities and decision making.
Involvement in Certain Legal Proceedings
To the best of our knowledge, none of our directors or executive officers have, during the past ten years, been involved in any legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K.
Risk Oversight
The Board oversees risk management related to the Company and its business as a whole, including its strategy, business performance, capital structure, management selection, compensation programs, stockholder engagement, corporate reputation, and ethical business practices. The Board discharges various aspects of its oversight responsibilities through its standing committees, which in turn report to the Board regularly regarding their activities. The Audit Committee represents the Board by periodically reviewing the Company’s accounting, reporting and financial practices, including the integrity of its financial statements and the surveillance of administrative and financial controls, as well as enterprise risk management, cyber risk and review of related party transactions. Through its regular meetings with management, including the finance, legal, internal audit and information technology functions, the Audit Committee will review and discuss all significant areas of the Company’s business and summarize for the Board all areas of risk and the appropriate mitigating factors. The Nominating and Corporate Governance committee provides oversight over compliance with legal and regulatory requirements, ethics and whistleblower matters. The Compensation Committee reviews the Company’s incentive compensation arrangements to determine whether they encourage excessive risk-taking and discuss with management the relationship between risk management policies and practices and compensation. In addition, the Board receives periodic detailed operating performance reviews from management.
28
Code of Ethics; Insider Trading Policy
The Board has adopted a code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Our code of business conduct and ethics and corporate governance guidelines are available under the Corporate Governance Section of our website at ir.envoymedical.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of our code of business conduct and ethics. The reference to our website address does not constitute incorporation by reference of the information contained in or available or accessible through our website, and you should not consider it to be a part of this Proxy Statement.
The Board has adopted a Policy on Inside Information and Insider Trading (the “
Policies and Practices for Granting Certain Equity Awards
29
MEETINGS AND COMMITTEES OF THE BOARD OF DIRECTORS
During 2025, the Board met 11 times. The standing committees of the Board are the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. During 2025, the Audit Committee met nine times, the Compensation Committee met five times, and the Nominating and Corporate Governance Committee met five times. All directors attended at least 75% of the meetings of the board of directors and any committees on which they served.
Executive Sessions; Attendance at Annual Meeting of Stockholders
The independent members of the Board regularly meet outside the presence of management. The Audit Committee has adopted a policy of meeting with the company’s independent auditors in executive session, without management being present, and also meets in executive session to discuss other matters as determined by the Audit Committee on a regular basis. During 2025, the members of the Audit Committee met in executive session six times, at each regular meeting. The Board’s policy is that each member of the Board should attend our annual meetings of stockholders whenever practical. Each of the directors attended the 2025 Annual Meeting.
Audit Committee
We have established an Audit Committee in accordance with Section 3(a)(58)(A) of the Exchange Act. The primary duties and responsibilities of our Audit Committee are to oversee (1) the integrity of our accounting and financial reporting processes and the audits of our financial statements; (2) our systems of internal controls; (3) our Code of Ethics; and (4) our compliance with legal and regulatory requirements. In addition, our Audit Committee appoints and monitors the independence, qualifications and performance of our independent auditors, provides an avenue of communication between our independent auditors, management and the Board, and reviews and approves related party transactions as required by the Nasdaq Listing Rules.
Ms. Kantor, Ms. Patel, and Ms. Smith-Gomez are the members of our Audit Committee. The members of the Audit Committee are “independent directors” as that term is defined in Rules 5605(a)(2) and 5605(c)(2)(A) of the Nasdaq Listing Rules and Rule 10A-3 of the Exchange Act. The Board has determined that Ms. Kantor is an “audit committee financial expert” as defined by Item 407(d)(5)(ii) of Regulation S-K. The Audit Committee operates under a written charter that satisfies the applicable standards of the SEC and the Nasdaq Listing Rules.
Compensation Committee
We have established a Compensation Committee, which sets the compensation of our chief executive officer and other executive officers. The Compensation Committee also approves the issuance of stock options and other awards that may be granted under our equity compensation plans. Additionally, the Compensation Committee reviews and evaluates, on an annual basis, the Compensation Committee charter and performance.
Our Compensation Committee has approved the compensation arrangements currently in place for our named executive officers. The Compensation Committee evaluates the performance of our Chief Executive Officer and determines his compensation based on this evaluation without our Chief Executive Officer present during voting or deliberations on his compensation. With respect to the other named executive officers, the Compensation Committee considers the recommendations of our Chief Executive Officer as to performance evaluations and recommended compensation arrangements.
The Compensation Committee may approve executive compensation arrangements or, in its discretion, may recommend such matters to the full Board for approval. Pursuant to its charter, the Compensation Committee may delegate any of its responsibilities to a subcommittee comprised of one or more members of the Compensation Committee.
Ms. Patel, Mr. Brynelsen, and Mr. Crowe are the members of our Compensation Committee. The members of the Compensation Committee are “independent directors” as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules and qualify as “non-employee directors” under Rule 16b-3 of the Exchange Act.
30
Nominating and Corporate Governance Committee
We have established a Nominating and Corporate Governance Committee. The members of the Nominating and Corporate Governance Committee are “independent directors” as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules. The principal functions of the Nominating and Corporate Governance Committee are to:
• identify and evaluate potential candidates for the Board and committee positions;
• recommend to the Board a slate of nominees for election as directors at our annual meetings of stockholders;
• recommend to the Board individuals to be appointed to the Board in connection with vacancies or newly created director positions and the termination of directors for cause or other appropriate reasons;
• review the size and composition of the Board and its committees;
• make recommendations to the full Board regarding director compensation;
• oversee our corporate governance practices; and
• develop, recommend and oversee an annual evaluation process for the Board and management.
Ms. Smith-Gomez, Ms. Kantor, and Mr. Brynelsen are the members of our Nominating and Corporate Governance Committee.
31
QUALIFICATIONS OF CANDIDATES FOR ELECTION TO THE BOARD
The Nominating and Corporate Governance Committee identifies and recommends candidates it believes are qualified to stand for election as directors of Envoy Medical or to fill any vacancies on the Board. In identifying director candidates, the Nominating and Corporate Governance Committee may retain third party search firms.
In order to evaluate and identify director candidates, the Nominating and Corporate Governance Committee considers the suitability of each director candidate, including the current members of the Board, in light of the current size, composition and current perceived needs of the Board. The Nominating and Corporate Governance Committee seeks highly qualified and experienced director candidates and considers many factors in evaluating such candidates, including understanding of a director’s role and responsibilities; ability to understand basic financial statements; knowledge of the Company’s business and industry; high moral character and judgment; willingness to abide by the Company’s policies and applicable rules and regulations; ability to devote requisite time and energy toward fulfilling the Board’s responsibilities; and being able to work collegially with others. In addition, in evaluating directors and director nominees, the current composition of the Board shall be considered with respect to the breadth of skills, knowledge, and diversity represented by the Board. The Nominating and Corporate Governance Committee does not assign any particular weight or priority to any of these factors.
The Nominating and Corporate Governance Committee may review director candidates by reviewing information provided to it, through discussions with persons familiar with the candidate, or other actions that the Nominating and Corporate Governance Committee deems proper. After such review and consideration, the Nominating and Corporate Governance Committee designates any candidates who are to be interviewed and by whom they are to be interviewed. After interviews, the Nominating and Corporate Governance Committee recommends for Board approval of any new directors to be nominated.
The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders in the same manner that it considers all director candidates. Stockholders who wish to nominate a qualified candidate for the 2027 Annual Meeting must submit such nomination in writing to our Corporate Secretary, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110, in accordance with the stockholder proposal requirements summarized under “Stockholder Proposals” below.
BOARD OF DIRECTORS VACANCIES
Our Bylaws authorize only the Board to fill vacant directorships, including newly created seats. In addition, the number of directors constituting the Board is permitted to be set only by a resolution adopted by the Board. These provisions prevent a stockholder from increasing the size of the Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board but promotes continuity of management.
STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS
Our stockholders may contact the Board, or any committee of the Board, by regular mail at Secretary, Envoy Medical, Inc., 4875 White Bear Parkway, White Bear Lake, MN 55110. All communications will be reviewed by management and, if appropriate to the duties and responsibilities of the Board, forwarded to the appropriate director or directors or to the full Board, as appropriate.
32
DIRECTOR COMPENSATION
The Company has approved and implemented a compensation program for its non-employee directors pursuant to which it pays its directors annual cash retainers for board and committee service. Directors are paid an annual cash retainer of $40,000, with the Board chair and the chair of the Audit Committee receiving an additional retainer of $60,000 per year and the chairs of the Compensation Committee and Nominating and Corporate Governance Committee receiving an additional $10,000 per year.
The Nominating and Corporate Governance Committee has also approved regular stock option awards to purchase 25,000 shares of Class A Common Stock for each director with options to purchase an additional 37,500 shares of Class A Common Stock issued to the Board chair and the chair of the Audit Committee, which awards will be made annually on the date of our annual meeting with an exercise price equal to the closing price of our Class A Common Stock on Nasdaq on such date. This plan may be adjusted at any time. All directors will also be reimbursed for their reasonable out-of-pocket expenses incurred while serving as directors.
The director compensation plan will be designed to attract and retain the most qualified individuals to serve on the Board in line with that of other public companies of a similar size. The Board, on the recommendation of our Compensation Committee, is responsible for reviewing and approving any changes to the directors’ compensation arrangements.
The table below sets forth the compensation paid to our non-employee directors during the fiscal year ended December 31, 2025.
|
Name |
Fees |
Option Awards |
Other |
Total |
|||||||
|
Chuck R. Brynelsen |
$ |
100,000 |
$ |
35,819 |
— |
$ |
135,819 |
||||
|
Michael Crowe |
$ |
40,000 |
$ |
14,328 |
— |
$ |
54,328 |
||||
|
Susan Kantor |
$ |
100,000 |
$ |
35,819 |
— |
$ |
135,819 |
||||
|
Mona Patel |
$ |
47,500 |
$ |
14,328 |
— |
$ |
61,828 |
||||
|
Janis Smith-Gomez |
$ |
47,500 |
$ |
14,328 |
— |
$ |
61,828 |
||||
|
Glen A. Taylor(2) |
$ |
— |
|
— |
— |
$ |
— |
||||
____________
(1) The amounts shown in this column represent the grant date fair values of option awards granted in 2024 as computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification Topic 718.
(2) Mr. Taylor served on the Board through August 25, 2025. Mr. Taylor waived any director compensation based on his status as majority holder of our Class A Common Stock.
Security Ownership of Certain Beneficial Owners, Executive Management and Directors
The following table sets forth information known to us regarding the beneficial ownership of the Class A Common Stock as of March 20, 2026 by:
• each person who is known by us to be the beneficial owner of more than 5% of the outstanding shares of the Class A Common Stock;
• each current named executive officer and director of the Company; and
• all current executive officers and directors of the Company, as a group.
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and Warrants that are currently exercisable or exercisable within 60 days.
Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned Class A Common Stock.
33
The information below is based on an aggregate of [76,881,110] shares of Class A Common Stock issued and outstanding as of March 20, 2026. The table below does not reflect any possible redemptions from funds which acquired Class A Common Stock in the public markets and have not yet filed a corresponding Schedule 13G reflecting a change in ownership. In addition, the information below includes shares of Class A Common Stock issuable upon exercise of stock options, warrants, preferred stock, and other securities exercisable or convertible for shares of Class A Common Stock. Such shares are deemed outstanding for computing the percentage of the person holding such shares but are not deemed outstanding for computing the percentage of any other person. Unless otherwise indicated, the Company believes that all persons named in the table below have sole voting and investment power with respect to the voting securities beneficially owned by them.
|
Class A Common Stock |
|||||
|
Name of Beneficial Owner(1) |
Number of |
Percentage of |
|||
|
Five percent holders: |
|
||||
|
Glen A. Taylor(2) |
63,409,614 |
57.0 |
% |
||
|
Nantahala Capital Partners Limited Partnership |
7,650,000 |
9.9 |
% |
||
|
Named Executive Officers and Directors: |
|
||||
|
Brent T. Lucas(3) |
1,357,280 |
1.7 |
% |
||
|
Robert Potashnick(4) |
552,500 |
* |
|
||
|
Chuck R. Brynelsen(5) |
2,772,830 |
3.5 |
% |
||
|
Michael C. Crowe(6) |
35,938 |
* |
|
||
|
Susan J. Kantor(7) |
430,742 |
* |
|
||
|
Mona Patel(8) |
873,646 |
1.1 |
% |
||
|
Janis Smith-Gomez(9) |
41,146 |
* |
|
||
|
All current directors and executive officers as a group (7 persons) |
6,064,082 |
7.1 |
% |
||
____________
* Represents beneficial ownership of less than 1%.
(1) Unless otherwise noted, the business address of each of the beneficial owners is c/o Envoy Medical, Inc., 4875 White Bear Pkwy, White Bear Lake, MN 55110.
(2) Includes (i) 21,703,607 shares of Class A Common Stock held by Mr. Taylor directly, (ii) 2,526,058 shares of Class A Common Stock held by Taylor Sports Group of which Mr. Taylor is the owner and chairman, (iii) 4,810,384 shares of Class A Common Stock held by GAT Funding, LLC, which Mr. Taylor controls, (iv) 869,565 shares of Class A Common Stock issuable upon the conversion of 1,000,000 shares of Series A Preferred Stock, which were issued to GAT Funding, LLC pursuant to the convertible promissory note that the Company entered into with GAT Funding, LLC concurrently with the Business Combination Agreement, (v) 3,500,000 shares issuable upon exercise of stock purchase warrants held by GAT Funding, LLC, which Mr. Taylor controls, and (iv) 30,000,000 shares issuable upon exercise of stock purchase warrants held by Mr. Taylor directly.
(3) Includes (i) 315,801 shares of Class A Common Stock held directly by Mr. Lucas, (ii) 849,203 shares of Class A Common Stock issuable upon exercise of stock options, (iii) 110,987 shares of Class A Common Stock issuable upon exercise of Public Warrants, and (iv) 1,972 shares of Class A Common Stock held by Mr. Lucas’s spouse, and (v) 100,000 shares issuable upon exercise of stock purchase warrants held by Mr. Lucas directly.
(4) Includes 340,000 shares issuable upon exercise of stock purchase warrants.
(5) Includes 122,830 shares of Class A Common Stock issuable upon exercise of stock options and 1,600,000 shares issuable upon exercise of stock purchase warrants.
(6) Represents shares of Class A Common Stock issuable upon exercise of stock options.
(7) Includes 102,865 shares of Class A Common Stock issuable upon exercise of stock options and 153,840 shares issuable upon exercise of stock purchase warrants.
(8) Includes 41,146 shares of Class A Common Stock issuable upon exercise of stock options and 500,000 shares issuable upon exercise of stock purchase warrants.
(9) Represents shares of Class A Common Stock issuable upon exercise of stock options.
34
EXECUTIVE OFFICERS
The following table identifies our current executive officers, the positions they hold, and their current age. Our executive officers are appointed by the Board of Directors to hold office until their successors are elected or their earlier death, resignation or removal.
|
Name |
Age |
Positions |
||
|
Brent T. Lucas |
44 |
Chief Executive Officer; Director |
||
|
Robert M. Potashnick |
46 |
Interim Chief Financial Officer |
For biographical information about Mr. Lucas, please refer to Proposal 1 entitled “Election of Directors.” Biographical information about Mr. Potashnick is as follows:
Robert Potashnick — Interim Chief Financial Officer
Robert Potashnick has provided consulting services through Oasis Business Consulting LLC since October 2024. Previously, Mr. Potashnick served as the Chief Financial Officer of Flutterbee Education Group from January 2024 to October 2024 and FOXO Technologies Inc. (NYSE American: FOXO) from January 2021 to September 2023. From 2017 to 2020, Mr. Potashnick served in capital planning and business development finance roles at UnitedHealth Group (NYSE American: UNH). Before that, from 2010 to 2017, Mr. Potashnick worked as a certified public accountant at PricewaterhouseCoopers LLP. Mr. Potashnick holds a Bachelor of Arts degree in Economics from Northwestern University, a Master’s Degree in Accountancy from the University of Illinois, and an MBA (Finance/Strategy) from DePaul University.
35
EXECUTIVE COMPENSATION
The policies of the Company with respect to the compensation of its executive officers are administered by the Board in consultation with the Compensation Committee. We may also rely on data and analyses from third parties, such as compensation consultants, in connection with its compensation programs. We intend to design and implement programs to provide for compensation that is sufficient to attract, motivate and retain executives of the Company and potential other individuals and to establish an appropriate relationship between executive compensation and the creation of stockholder value.
For the year ended December 31, 2025, our named executive officers were Brent T. Lucas, our Chief Executive Officer, David R. Wells, our former Chief Financial Officer, and Robert M. Potashnick, our Interim Chief Financial Officer.
Summary Compensation Table
The following table sets forth information concerning the compensation of the named executive officers for the years ended December 31, 2025 and 2024.
|
Name and Principal Position |
Year |
Salary |
Option |
Nonequity |
All Other |
Total |
||||||||||||
|
Brent T. Lucas |
2025 |
$ |
400,000 |
|
— |
$ |
62,000 |
|
— |
|
$ |
462,000 |
||||||
|
Chief Executive Officer and Director |
2024 |
$ |
400,000 |
|
— |
|
— |
$ |
10,509 |
(2) |
$ |
410,509 |
||||||
|
Robert M. Potashnick |
2025 |
$ |
180,766 |
(3) |
— |
|
— |
|
— |
|
$ |
180,766 |
||||||
|
Interim Chief Financial Officer |
|
|
|
|
|
|
||||||||||||
|
David R. Wells(4) |
2025 |
$ |
122,106 |
|
— |
|
— |
$ |
318,548 |
(5) |
$ |
440,6564 |
||||||
|
Former Chief Financial Officer |
2024 |
$ |
315,006 |
|
— |
$ |
39,875 |
$ |
9,702 |
(6) |
$ |
364,583 |
||||||
____________
(1) The amounts shown in this column represent the grant date fair values of option awards as computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification Topic 718. Refer to “Note 12 — Stock-Based Compensation” in the audited financial statements included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the assumptions used in calculating the award amount.
(2) Represents Company 401(k) plan matching contributions.
(3) Represents consulting fees paid to Mr. Potashnick’s company Oasis Business Consulting LLC.
(4) Mr. Wells ceased serving as Chief Financial Officer on May 16, 2025.
(5) Includes $315,000 in separation compensation and $3,548 Company 401(k) plan matching contributions.
(6) Represents Company 401(k) plan matching contributions.
Outstanding Equity Awards at Fiscal Year-End
The following table presents information regarding outstanding equity awards held by Envoy Medical’s named executive officers as of December 31, 2025:
|
Option Awards |
|||||||||||
|
Name |
Grant Date |
Number of |
Number of |
Option |
Option |
||||||
|
Brent T. Lucas |
10/15/2023 |
818,656 |
61,093 |
$ |
2.40 |
10/15/2033 |
|||||
|
Robert M. Potashnick |
— |
— |
— |
|
— |
— |
|||||
|
David R. Wells |
— |
— |
— |
|
— |
— |
|||||
____________
(1) Options to purchase 659,811 shares vested on October 15, 2023, and the remaining 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
36
Narrative Disclosure to Summary Compensation Table
The primary element of compensation for Envoy Medical’s named executive officers is base salary. Named executive officers may also be eligible from time to time to be awarded annual performance bonuses and may be issued stock options or other stock-based compensation. Envoy Medical’s named executive officers further participate in employee benefit plans and programs that Envoy Medical offers to its other employees, as described below.
Envoy Medical’s executive compensation program is designed to attract, retain and reward key employees, to incentivize them based on the achievement of key performance goals, and to align their interests with the interests of Envoy Medical’s stockholders.
Annual Base Salaries
The base salaries of Envoy Medical’s named executive officers are subject to periodic review by the Compensation Committee of the Board. Mr. Lucas received a base salary of $400,000 for each of fiscal years 2025 and 2024. Mr. Wells received a base salary of $122,106 and $315,006 for fiscal years 2025 and 2024, respectively, with the 2025 base salary annualized based on the portion of the year served.
Mr. Potashnick serves as Interim Chief Financial Officer as a consultant and not an employee. He is paid an hourly fee of $200 per hour, with a minimum of 100 hours and a maximum of 150 hours per month (subject to approval of additional hours by the Company), through his consulting company.
Non-Equity Incentive Compensation
Envoy Medical’s named executive officers may be awarded an annual bonus in the discretion of the Compensation Committee. For 2025, Mr. Lucas earned a bonus of $62,000. For 2024, Mr. Wells was paid an annual bonus of $39,875.
Severance Compensation
Following Mr. Wells’ separation from employment with the Company, he became entitled to $315,000 of severance pay, approximately $210,000 of which was paid in the year ended December 31, 2025 and approximately $105,000 of which has been or will be paid in the year ended December 31, 2026.
Executive Officer Employment Agreements
Brent T. Lucas
On October 16, 2023, the Company entered into a written employment agreement (the “Lucas Employment Agreement”) with its Chief Executive Officer, Brent T. Lucas. The Lucas Employment Agreement has an initial term of five years, subject to automatic renewal for an additional one-year terms unless either party provides 90 days’ written notice of non-renewal. The Lucas Employment Agreement provides for an initial base salary of $400,000 annually, subject to periodic review and increase by the Compensation Committee. The base salary may not be decreased unless it is part of a salary reduction applicable to all employees or all management employees, and with Mr. Lucas’ consent.
Under the Lucas Employment Agreement, Mr. Lucas is entitled to participate in the restricted stock unit or other long-term equity incentive compensation plan, program or arrangement (“Incentive Compensation”) expected to be adopted by the Company and generally made available to the Company’s executive officers.
If the Company terminates Mr. Lucas’s employment for any reason (i) other than “Cause;” (ii) other than death; (iii) other than “Disability;” or if Mr. Lucas resigns for “Good Reason,” the Company will pay him (v) earned but unpaid salary, and earned but unpaid Incentive Compensation, if applicable as of the date of termination of the Lucas Employment Agreement; (w) the benefits, if any, to which he is entitled as a former employee; (x) continuation of health insurance coverage for two years (or until he is covered under the health insurance of a new employer); (y) payment for the cost of an executive search firm reasonably selected by Mr. Lucas; and (z) a continuation of base salary for one year after the date of termination, payable monthly.
37
In the event of Mr. Lucas’s death or Disability (as defined in the Lucas Employment Agreement), the Company will pay Mr. Lucas or his surviving beneficiary (i) in a lump sum within thirty days following the date of his death or termination for Disability, any other benefits to which Mr. Lucas is then entitled under the Company’s applicable benefit plans and programs as of such date, and (ii) in a lump sum within thirty days following the date of his death or termination for Disability, his earned but unpaid salary as of such date. In addition, in the event the Lucas Employment Agreement is terminated for Disability, Mr. Lucas shall receive severance pay with an aggregate value equal to the sum of one year of his base salary at the rate in effect on the date of such termination for Disability.
Robert M. Potashnick
Mr. Potashnick was engaged as Interim Chief Financial Officer through his wholly owned entity, Oasis Business Consulting, LLC (“Oasis”), pursuant to a Consulting Agreement dated effective June 23, 2025 (the “Consulting Agreement”). Pursuant to the terms of the Consulting Agreement, the Company will pay Oasis a fee of $200 per hour for Mr. Potashnick’s service with a minimum of 100 hours and a maximum of 150 hours per month (subject to approval of additional hours by the Company). The Consulting Agreement had an initial one-year term, subject to a requirement to terminate or renew 90 days prior to the completion of the term. The Consulting Agreement has been renewed and is currently continuing on a month-to-month basis. The Consulting Agreement does not provide for any type of severance or other post-termination compensation.
Compensation Committee Interlocks and Insider Participation
As a smaller reporting company, we are not required to provide disclosure pursuant to this item.
Compensation Committee Report
As a smaller reporting company, we are not required to provide disclosure pursuant to this item.
Equity Compensation Plan Information
|
Plan category |
Number of |
Weighted- |
Number of |
||||||
|
Equity compensation plans approved by security holders |
|
|
|
||||||
|
2023 Equity Incentive Plan |
2,257,024 |
(1) |
$ |
2.18 |
1,742,976 |
(2) |
|||
|
2023 Employee Stock Purchase Plan |
245,249 |
|
|
0.96 |
54,751 |
(3) |
|||
|
Equity compensation plans not approved by security holders |
— |
|
|
— |
— |
|
|||
|
Total |
2,502,273 |
|
$ |
2.06 |
1,797,727 |
|
|||
____________
(1) Represents options to purchase 2,257,024 shares of Class A Common Stock.
(2) 4,000,000 shares of Class A Common Stock have been authorized for issuance pursuant to awards under the 2023 Equity Incentive Plan, provided that pending approval of proposed amendment to the 2023 Plan an additional 6,000,000 shares of Class A Common Stock will be authorized for issuance under the 2023 Plan (as described in Proposal 4 above).
(3) 300,000 shares of Class A Common Stock have been authorized for issuance pursuant to awards under the ESPP, provided that pending approval of proposed amendment to the 2023 Plan an additional 1,200,000 shares of Class A Common Stock will be authorized for issuance under the ESPP (as described in Proposal 5 above).
38
DELINQUENT SECTION 16(a) REPORTS
Section 16(a) of the Exchange Act requires the Company’s officers and directors, and persons who own more than 10% of a registered class of the Company’s equity securities, to file reports of ownership on Form 3 and changes in ownership on Form 4 or Form 5 with the SEC. Such officers, directors and 10% stockholders are also required by SEC rules to furnish the Company with copies of all Section 16(a) forms they file.
Based solely on its review of the copies of such forms received by it, or written representations from certain reporting persons, the Company believes that, during the fiscal year ended December 31, 2025, all Section 16(a) filing requirements applicable to its officers, directors and 10% stockholders were timely complied with, other than a Form 4 filed by Mr. Taylor with respect to warrants issued on June 26, 2025.
39
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Except as described below, since January 1, 2025, there were no related party transactions arising or existing requiring disclosure under applicable Nasdaq Listing Rules or SEC rules and regulations.
March 2025 Note
On March 6, 2025, the Company issued a promissory note (the “2025 Note”) to GAT Funding, LLC (“GAT”), an entity controlled by Glen A. Taylor, who was a member of the Company’s board of directors until August 25, 2025 and owns, directly or indirectly, approximately 35.6% of the outstanding shares of the Company’s Class A Common Stock, pursuant to which the Company borrowed the principal amount of $10,000,000 (the “2025 Term Loan” and, together with $30,000,000 of prior loans from GAT to the Company, the “Term Loans”). The 2025 Note had a five-year term and a maturity date of March 6, 2030. The principal amount of the 2025 Term Loan bore interest at a rate of 8.0% per annum and was payable quarterly in arrears after the second anniversary of the 2025 Note. Interest accrued and was not required to be paid during the first two years of its term.
As a commitment fee, the Company agreed to issue GAT warrants to purchase 375,000 shares of its Class A Common Stock for each $2,500,000 of principal funded under the 2025 Note. The warrants have an exercise price equal to the closing price on the date of funding of the applicable tranche and a termination date as of the second anniversary of the initial closing under the 2025 Note. The Company issued GAT warrants to purchase 750,000 shares of Class A Common Stock at an exercise price of $1.35 per share on March 6, 2025 and warrants to purchase 750,000 shares of Class A Common Stock at an exercise price of $1.48 on June 26, 2025 (collectively, the “March 2025 Note Warrants” and, together with the February 2024 Note Warrants and the August 2024 Note Warrants, the “Term Loan Warrants”).
Debt Forgiveness
On August 25, 2025, the Company and GAT entered into a Satisfaction of Promissory Notes (the “Satisfaction Agreement”). Pursuant to the terms of the Satisfaction Agreement, all of the Company’s principal and interest obligations under the Term Loans was deemed fully satisfied in exchange for a one-time payment by the Company to GAT in the amount of $100,000. The Company made the $100,000 payment to GAT on August 25, 2025, which resulted in full satisfaction of the principal and interest amounts owed under the Term Loans.
Voting and Warrant Extension Agreement
On September 4, 2025, the Company, GAT, Taylor Sports Group, Inc. (an entity controlled by Mr. Taylor) (“Taylor Sports”), and Mr. Taylor entered into a Voting and Warrant Extension Agreement (the “Voting and Extension Agreement”). Pursuant to the Voting and Warrant Extension Agreement, GAT, Taylor Sports, and Mr. Taylor (collectively, the “Taylor Parties”) agreed to vote any shares beneficially owned by the Taylor Parties in favor of any proposal required to be approved by the Company’s stockholders to ensure compliance with the Nasdaq Listing Rules. The Taylor Parties’ voting obligations will be in effect through December 31, 2028. In exchange for such voting agreements, the Company agreed to extend the exercise term for each of the Term Loan Warrants to December 31, 2028 and to register the resale of the shares of the Company’s Class A Common Stock held by the Taylor Parties. The rights and obligations of the Taylor Parties under the Voting and Extension Agreement would be transferable to and binding upon any successor or transferee of the Taylor Parties.
Pursuant to the Voting and Extension Agreement, the Company also agreed to register shares of the Company’s Class A Common Stock held or acquirable by the Taylor Parties upon the request of the Taylor Parties delivered on or after March 31, 2026.
Facility Lease
The Company leases its headquarters office space in Minnesota from Taylor Corporation, an entity controlled by Mr. Taylor, pursuant to a Lease Agreement, dated May 20, 2016, as amended to date (the “Lease”). The term of the Lease runs through 2030. The Company paid an aggregate of approximately $206,000 under the lease in 2025 for rent, repayment of build out expenses, and shared utilities and other operating expenses for the facility.
40
February 2026 Stock and Warrant Financing
On February 13, 2026, the Company completed the offering (the “Offering”) of an aggregate of (i) 47,946,150 shares of the Company’s Class A Common Stock (the “Shares”), (ii) 27,053,850 pre-funded warrants (the “Issued Pre-Funded Warrants”) to purchase 27,053,850 shares of Class A Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Class A Common Stock and/or pre-funded warrants, and (iv) 75,000,000 Series A-2 Warrants to purchase 75,000,000 shares of Class A Common Stock and/or pre-funded warrants. For each Share (or Issued Pre-Funded Warrant) purchased, the investors received accompanying Common Warrants in the amount of six-tenths (0.6) of a Series A-1 Warrant and one Series A-2 Warrant. The combined purchase price in the February 2026 Offering was $0.40 per Share (or $0.3999 per Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants.
Company directors, officers, 10% stockholders, and their immediate family members participated in the offering as follows:
• Vali Orandi, who is the father-in-law of our Chief Executive Office and director, purchased 500,000 Shares and an aggregate of 800,000 Common Warrants for $200,000;
• Mr. Brynelsen, a director, purchased 1,000,000 Shares and an aggregate of 1,600,000 Common Warrants, for $400,000;
• Ms. Patel, a director, purchased 312,500 Shares and an aggregate of 500,000 Common Warrants for $125,000;
• Mr. Taylor purchased 18,750,000 Shares and an aggregate of 30,000,000 Common Warrants for $7,500,000.
Each of the individuals listed above participated in the Offering on the same terms as were negotiated with outside investors.
41
AUDIT COMMITTEE REPORT
Management is responsible for Envoy Medical’s financial reporting process, including the system of internal controls, and for preparing Envoy Medical’s financial statements in accordance with accounting principles generally accepted in the United States of America. Our independent registered public accounting firm is responsible for auditing those financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States of America. The Audit Committee’s responsibility is to monitor and review these processes. The members of the Audit Committee rely, without independent verification, on the information provided to them and on the representations made by Envoy Medical’s management and the independent registered public accounting firm.
During the year ended December 31, 2025, the Audit Committee, consisting of Susan J. Kantor (Chair), Mona Patel, and Janis Smith-Gomez held nine meetings. The meetings were designed to, among other things, facilitate and encourage communication among the Audit Committee, management and Envoy Medical’s independent registered public accounting firm, Grant Thornton LLP (“Grant Thornton”). The Audit Committee discussed with Grant Thornton the overall scope and plans for its 2025 audit. The Audit Committee met with Grant Thornton, with and without management present, to discuss the results of its examinations and its evaluations of Envoy Medical’s system of internal controls.
During the meetings held in 2025, the Audit Committee reviewed and discussed, among other things:
• Envoy Medical’s financial statements, its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and any reports received from the independent registered public accounting firm;
• recent accounting pronouncements and the Company’s significant accounting policies;
• disclosure controls and procedures and internal controls over financial reporting;
• review and approval of certain related party transactions; and
• engagement of Envoy Medical’s independent registered public accounting firm.
In March 2026, the Audit Committee reviewed and discussed the 2025 audited financial statements and notes to the financial statements proposed for inclusion in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with management and Grant Thornton, including a discussion of the application of accounting principles generally accepted in the United States, the reasonableness of significant judgments, and the clarity of disclosures in the financial statements. The Audit Committee also met with management and Grant Thornton to review, discuss, and approve for filing the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, including a discussion of the application of accounting principles generally accepted in the United States, the reasonableness of significant judgments, and the clarity of disclosures in the financial statements. Each meeting to review and discuss the Company’s Annual and Quarterly Reports included executive sessions in which the Audit Committee held discussions with Grant Thornton outside the presence of management.
The Audit Committee also has discussed with our independent registered public accounting firm the firm’s independence from management, including whether the provision of non-audit services is compatible with maintaining the firm’s independence, and matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board. The Audit Committee received the written disclosures and the letter from the independent registered public accounting firm required by the Public Company Accounting Oversight Board regarding such firm’s communications with the Audit Committee concerning independence and has discussed with such firm its independence.
Based on this review and prior discussions with management and the independent registered public accounting firm, the Audit Committee recommended to the Board that Envoy Medical’s audited financial statements be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as filed with the SEC.
Audit Committee
Susan J. Kantor (Chair)
Mona Patel
Janis Smith-Gomez
42
STOCKHOLDER PROPOSALS
Any stockholder desiring to submit a proposal for action by the stockholders at our next annual meeting, which will be our 2027 Annual Meeting, must satisfy the requirements set for in the advance notice provision under our Bylaws. To be timely submitted for our 2027 Annual Meeting, any such proposal must be delivered in writing to our Corporate Secretary at the principal executive offices of the Company between the close of business on January 12, 2027 and the close of business on February 11, 2027. If the date of the 2027 Annual Meeting is advanced more than 30 days prior to or delayed by more than 70 days after the first anniversary of the 2027 Annual Meeting, notice by the stockholder must be delivered not earlier than the close of business on the 120th day prior to the 2027 Annual Meeting and not later than the close of business on the later of the 90th day prior to the 2027 Annual Meeting or, if later, the 10th day following the day on which public announcement of the date of the 2027 Annual Meeting is first made. Notice sent to the Company must comply with the requirements set forth in the Company’s Bylaws. You are advised to review the Company’s Bylaws, and due to the complexity of the respective rights of the stockholders and the Company in this area, you are advised to consult with your legal counsel with respect to such rights.
In addition to satisfying the foregoing provisions of our Bylaws, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-9 under the Exchange Act no later than March 13, 2026, which is 60 days prior to the anniversary of the 2027 Annual Meeting.
In addition, any stockholder proposal intended to be included in the proxy statement for the 2027 Annual Meeting must also satisfy Rule 14a-8 of the Exchange Act and be received no later than December 3, 2026. If the date of the 2027 Annual Meeting is moved by more than 30 days from the first anniversary of the 2027 Annual Meeting, then notice must be received within a reasonable time before we begin to print and send proxy materials.
|
By Order of the Board of Directors: |
||||
|
Dated: [April 2], 2026 |
/s/ Brent T. Lucas |
|||
|
Chief Executive Officer, Director |
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2025
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY [12], 2026.
The Notice, this Proxy Statement, and the Annual Report on Form 10-K are available at www.iproxydirect.com/coch and on the Investor Relations section of Envoy Medical’s website at ir.envoymedical.com.
43